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2ABSTRACT
Exhaled nitric oxide (FeNO) reflects eosinophilic airway inflammation and it can be used to diagnose and
phenotype asthma and predict treatment responses. However, smoking decreases FeNO and it is not clear if
FeNO has clinical value in smoking subjects with asthma.
We conducted a systematic review focusing on four basic characteristics and five clinical questions on using
FeNO in smokers with asthma. At least two authors independently screened search results, extracted data
and assessed quality of the included studies. Data were synthesised mainly by qualitative methods.
Twenty-two studies were included. FeNO is lower in smoking than in non-smoking asthmatics, but
importantly FeNO is higher in untreated smoking asthmatics than in healthy smokers. Information was
incomplete but there is some indication that FeNO might be useful in detecting eosinophilic airway
inflammation and in diagnosing asthma in smoking subjects. There was no data available to four of the five
clinical questions.
In conclusion, at the moment there is insufficient data to give specific guidelines on using FeNO in smoking
subjects, but although smoking decreases FeNO it does not seem to make FeNO measurement redundant.
FeNO is associated with asthma also in smokers and current results encourage conducting clinical trials on
FeNO in smokers with asthma.
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3INTRODUCTION
Asthma is a chronic airway disease usually characterised by mucosal inflammation, bronchial
hyperresponsiveness and variable airway obstruction leading to symptoms such as cough, chest tightness
and wheezing (1). The intensity and type of airway inflammation vary between individuals and many
phenotypes of asthma have been identified (2). Eosinophilic airway inflammation is a common and best
known inflammatory phenotype of asthma, but also neutrophilic and paucigranulocytic asthma have been
described. Although inflammation is pivotal in the pathogenesis of asthma, the diagnosis and follow-up of
asthma are currently mainly based on assessing symptoms and lung function.
As eosinophilic inflammation is particularly sensitive to treatment with inhaled corticosteroids (ICS) (3-6),
non-invasive markers of eosinophilic phenotype of asthma have been developed in order to guide ICS-
treatment in asthma. Nitric oxide (NO) is an important cellular signalling molecule that regulates pulmonary
blood flow, mucus production, ciliary activity and inflammation. Under normal circumstances NO is produced
at very low concentrations by constitutive NO synthases (endothelial NOS and neuronal NOS). In cases of
airway inflammation pro-inflammatory cytokines upregulate expression of inducible NOS producing higher
amounts of NO (7). Fractional exhaled nitric oxide (FeNO) is particularly associated with eosinophilic airway
inflammation (8-12). Since allergic asthma is eosinophilic in nature, elevated FeNO is associated also with
atopy among subjects with asthma (13). Treatment with ICS suppresses activity of eosinophilic inflammation,
and it efficiently decreases FeNO level (14), probably by inhibiting NFκB (15), an important transcription
factor regulating the expression of iNOS.
Active smoking is unfortunately almost as common among asthmatics as among healthy subjects (17).
Smoking is known to induce a macrophage and neutrophil driven chronic airway inflammation, but many
smoking asthmatics still have eosinophilic inflammation characteristic to asthma (18,19). As eosinophilic
inflammation is found also in smoking asthmatics, FeNO might be used to find eosinophilic phenotype of
asthma also in active smokers. However, smoking as such reduces FeNO (16,20) possibly by reducing the
availability of a cofactor tetrahydrobiopterin needed in NO synthesis (21,22) or by increased superoxide
synthesis by neutrophils that scavenges NO in chemical reactions preventing it from diffusing into exhaled
air. Therefore, the cut-off value of FeNO to find active eosinophilic airway inflammation among smokers
would probably have to be lower than among non-smokers. Due to the effect of smoking on FeNO, most of
the clinical studies assessing the value of FeNO in asthma have been conducted in non-smoking asthmatics
4only. In non-smokers with asthma, FeNO can be used to predict responsiveness to ICS and risk of
exacerbations (23). Hence, in non-smoking asthmatics titrating ICS treatment based on FeNO seems to
reduce number of exacerbations (24,25).
The aim and study questions
The aim of the present systematic review was to assess the basic characteristics and evidence for clinical use
of FeNO in smoking asthmatics. The detailed study questions were:
Basic characteristics of FeNO in relation to smoking and asthma:
1. Is FeNO associated with eosinophilic airway inflammation among smoking asthmatics?
2. Is FeNO associated with asthma control or asthma severity among smoking asthmatics?
3. Is FeNO lower in smoking than in non-smoking asthmatics?
4. Is  FeNO  among  smoking  asthmatics  a)  not  on  ICS-treatment  or  b)  on  ICS-treatment  higher  than
among healthy smoking individuals?
Clinical value of FeNO in relation to smokers with asthma:
5. Can FeNO be used as aid in diagnosing asthma in smoking subjects?
6. Does FeNO predict response to ICS treatment in steroid-naïve smoking asthmatics?
7. During maintenance ICS treatment, does FeNO measurement identify those smoking asthmatic
patients who are at risk of exacerbation?
8. During maintenance ICS treatment, does FeNO measurement identify those smoking asthmatic
patients who would benefit from augmented glucocorticoid treatment?
9. In smoking asthmatics, what is the clinical value of FeNO measurement in tailoring ICS treatment
compared to usual treatment strategy?
5METHODS
As this review considers several kinds of study designs depending on the research question (on basic
characteristics of FeNO, but also on the use of FeNO in diagnostics, prognostics and interventions), the review
does not apply only one framework but is multi-methodological. For example, intended tools for risk of bias
assessment of the included studies depend on the research question.
1. Criteria for considering studies for this review
Types of studies
We included studies in which FeNO measurement was conducted in smoking asthmatic subjects and the
sample size was at least 10 subjects per group. We included systematic reviews, randomised controlled trials,
controlled clinical trials, other comparative studies, observational studies, both prospective and
retrospective designs, published in English, German, Scandinavian languages and Hungarian.
Types of participants
We included studies on smoking asthmatic subjects in whom the diagnosis of asthma was based on reversible
or variable airway obstruction (1) in at least 80 % of participants with asthma. We placed no restrictions on
comorbidities in included subjects. Subjects without any diagnosed respiratory disease were classified and
included as healthy subjects. FeNO had to be measured using an online technique and measured at a
healthcare unit excluding home measurements (the standard flow rate is 50 ml/s but we allowed also the
use  of  other  flow  rates  in  the  included  studies).  For  reliable  online  FeNO  measurement,  the  age  of  the
subjects had to be at least 5 years (although this is obviously fulfilled in studies on active smokers).
In studies where FeNO was compared to other measures (e.g. questions 1 and 2), we placed no quality criteria
for these comparative measures, such as induced sputum eosinophil counts or asthma control, but we
accepted those as they were reported.
We decided to consider subjects as smokers if they were current smokers (without any restrictions e.g. on
frequency and amount of smoking) and as non-smokers if they were never-smokers or ex-smokers who had
not smoked for at least 6 months. Further, we decided that at least 80% of the non-smokers had to fulfil the
above-mentioned criterion for the study to be included. The reason for these decisions is that we anticipated
that the individual studies would have defined non-smokers very differently and useful information from the
studies would have been lost if e.g. only studies considering never-smokers would have been included. In
case the study reported characteristics and results separately both on never-smokers and ex-smokers, we
used never-smokers as the control group. Unfortunately, there is no solid information how rapidly and to
what extent quitting smoking affects FeNO, and therefore we decided in practical terms to set the time limit
6for quitting of smoking as 6 months. A sensitivity analysis was conducted to see if inclusion of ex-smokers as
non-smokers affects the results.
The criteria for anti-inflammatory medication and requirements for comparisons and outcome measures
depended on the study question and are listed in detail in Online Supplement 1.
2. Search strategy
The electronic literature searches were based on the following keywords: nitric oxide, exhalation, FeNO,
smoking, asthma. The searches were conducted in two stages. At first, we searched the following seven
electronic databases up to May 25, 2017 to track down systematic reviews and individual trials: MEDLINE
(OVID), Embase (OVID), Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Database of
Systematic Reviews, Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment
Database (HTA), and NHS Economic Evaluation Database (NHS EED).
We also searched the following two databases for ongoing studies: US National Institutes of Health Ongoing
Trials Register ClinicalTrials.gov (clinicaltrials.gov; searched 25 May 2017), and World Health Organization
International Clinical Trials Registry Platform (apps.who.int/trialsearch; searched 25 May 2017).
The searches were updated on 4 September 2018. Two new terms were added to Medical Subject Headings
in 2018 (Tobacco smoking, Pipe smoking) and these terms were added to the strategies where appropriate.
Search strategies are presented in Online Supplement 2.
In addition to searching the electronic databases, we screened the reference lists from the already identified
studies and review articles for any additional relevant studies.
We placed no language restrictions in searches, although for inclusion we assessed only reports published in
English, German, Scandinavian languages and Hungarian. If the information in the report was insufficient to
make the final assessment of inclusion or exclusion, we contacted the authors of the studies to obtain
additional information (authors of six studies were contacted).
We considered only studies with full-text reports for inclusion in this review because it has been shown that
discrepancies occur between data reported in abstracts and published full reports (26,27).
73. Data extraction and quality assessment
At least two authors independently screened search results, extracted data and assessed risk of bias of the
included studies. We extracted the following information: 1) on the study methods: study design, possible
length of follow-up, inclusion and exclusion process of participants (question 5); 2) on participants’
characteristics: location where the study was conducted, age, gender and numbers of participants in each
group,  severity  of  asthma,  forced  expiratory  volume  in  1  s  (FEV1), possible use of corticosteroids,
atopy/allergy, smoking habits of smoking subjects; 3) on characteristics of FeNO measurement: device and
exhalation flow rate; 4) details of reference standard in questions 1, 2 and 5; 5) analysis methods, results
reported in each study, and funding source.
Assessment of risk of bias
Risk of bias was assessed by using different tools depending on the study questions. A quality assessment
tool for diagnostic accuracy studies QUADAS-2 (28), Quality In Prognosis Studies tool QUIPS (29), and
Cochrane risk of bias tool (30) were used where and when appropriate. Details of the assessment of risk of
bias are given in Online Supplement 1.
4. Data synthesis
We synthesised data mainly by qualitative methods. The combined results in each research question and
comparison were based on the similarity of the results of the individual studies and on descriptive statistics,
if appropriate.
In the research question 3 and in one comparison of question 4 (with moderate numbers of included studies
with codirectional results), we decided to calculate proportional difference in FeNO values between study
groups in each study. Proportional difference in this review is defined as how many percentages lower the
FeNO values (in the group with lower values) were compared to the FeNO values in the comparison group.
We calculated 95% confidence intervals (CI) by Monte Carlo methods using R software version 3.4.2, ignoring
possible factors influencing variation at study level. We chose proportional difference as the statistic to
describe the results of different studies because there was much variability in flow rates and statistics used
between studies. Studies reported their results e.g. as means with SDs or medians with interquartile ranges
(IQR) or geometric means with 95% CIs. The distributions of FeNO values in most studies were skewed, and
it was impossible to standardize different statistics of the studies in another way. We present only ranges of
the percentages of differences in each comparison because the values varied much (and we do not present
an average magnitude of the percentage difference in FeNO values based on all included data at each
comparison).
8In research question 3 with non-smokers as controls, we included never smokers and also ex-smokers who
had quit smoking for at least 6 months earlier as non-smokers in the primary analysis. To assess the effect of
including also ex-smokers and not only never smokers as non-smokers, we undertook a sensitivity analysis
to assess the robustness of our results. In the sensitivity analysis we excluded studies with ex-smokers and
studies not explicitly stating that only never-smokers had been included as controls.
9Results
Search results		
Twenty-two studies were included. The processing of search results is presented in Figure 1. Detailed reasons
for exclusion of 16 studies are presented in Online Supplement 3 (main reasons for exclusions were: asthma
diagnosis of subjects or smoking status did not fulfil the inclusion criteria assessed for this review).
Figure 1. Flow chart of search results.
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Characteristics of included studies
The included 22 studies involved in total 5656 subjects (smoking and non-smoking asthmatics and smoking
healthy subjects). The studies provided data for all the research questions on basic characteristics (three
studies for question 1; two for question 2; 16 for question 3; and 9 for question 4) but for only one of the
clinical questions (3 studies for question 5). The designs of the studies in questions 1 to 4 varied much but
our research questions considered mainly cross-sectional data of the studies. There was marked variation
between studies regarding inclusion criteria of subjects, severity of asthma and use of anti-inflammatory
medication in asthmatics, proportion of atopics, smoking habits, and FeNO measurement (e.g. exhalation
flow rate). In many studies, there was incomplete or missing information on these factors having influence
on FeNO value. Detailed descriptions of the included 22 studies and results of each study per research
question are provided in Online Supplements 4-9.
Results per research questions
1. Is FeNO associated with eosinophilic airway inflammation among smoking asthmatics?
Summary: There is incomplete information, but based on three studies (two with positive and one with
negative finding) there is some indication that FeNO may be useful in detecting eosinophilic airway
inflammation in smoking asthmatics.
Berry and colleagues (31) concluded that in smoking asthmatics, FeNO was not closely related to sputum
eosinophil count and FeNO did not identify subjects with sputum eosinophil count > 3% (113 smoking
asthmatics, AUC = 0.63, 95% CI 0.48 to 0.78, p = 0.10). On the contrary, Hillas and colleagues (32) found that
the predictive performance of FeNO to detect purely eosinophilic phenotype (sputum eosinophilis ≥ 3% and
neutrophils < 60%) was satisfactory (40 smoking asthmatics, AUC of ROC = 0.880, 95% CI 0.74 to 0.96, p <
0.0001). Schleich and colleagues (33) concluded that FeNO is able to identify the presence of sputum
eosinophilia ≥ 3% in unselected patients with asthma with reasonable accuracy as long as FeNO thresholds
are adjusted for high doses of ICS, atopy and smoking status. Based on multiple regression analyses, they
found PPVs ranging from 52% to 62% and NPVs ranging from 76% to 89% depending on the covariates (such
as smoking) included in the analyses. By simple regression analysis with smoking as the only covariate, the
study reported PPV of 59% and NPV of 78%, for FeNO cut-off value of 28 ppb, (p-value 0.066). See Online
Supplement 4 for details.
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2. Is FeNO associated with asthma control or asthma severity among smoking asthmatics?
Summary: Based on two studies FeNO is rather poorly associated with the level of asthma control in smoking
asthmatics but based on one follow-up study change in FeNO between visits is related to simultaneous change
in asthma control. There were no studies on FeNO and asthma severity.
Kostikas and colleagues (34) evaluated the diagnostic performance of FeNO to identify patients with partly
controlled or uncontrolled asthma defined according to GINA guidelines. FeNO identified asthma control
better in ICS-untreated smokers than in ICS-treated smokers [AUC (95% CI) for the optimum cut-point of
FeNO > 19 ppb was 0.680 (0.492 to 0.833, p=0.059) and for the optimum cut-point of FeNO > 23 ppb it was
0.597 (0.449 to 0.733, p=0.256)]. They further stated that high FeNO values (over 30 ppb) are indicative of
poor asthma control even in ICS-treated smoking asthmatics (PPV of 83%).
Michils and colleagues (35) evaluated the diagnostic performance of FeNO for the identification of patients
with controlled asthma defined as ACQ score < 1.5. The study reported PPV of 30%, NPV of 81%, accuracy of
53% and p-value of 0.39 for the optimal FeNO cut-off value of 25ppb.
Michils and colleagues studied also whether change in FeNO value between two visits is related to
simultaneous change in asthma control and they found that sequential changes in FeNO are related to
changes in asthma control in smokers. The study showed that in smoking asthmatics with uncontrolled
asthma a FeNO reduction of < 20% between visits would indicate that asthma remained uncontrolled
(analysed as change from uncontrolled [ACQ score ≥ 1.5] to controlled [ACQ score < 1.5] asthma as a positive
event, then the cut-off value for decrease in FeNO, which had the highest NPV [82%] for establishing control
was 20%; accuracy 67%, p-value of 0.016). Conversely, when asthma is controlled, an FeNO increase of < 50%
would indicate that asthma remained controlled (analysed as change from controlled [ACQ score < 1.5] to
uncontrolled [ACQ score ≥ 1.5] asthma as a positive event, then the cut-off value for an increase in FeNO,
which had the highest NPV [89%] for a change to uncontrolled asthma was 50%; accuracy 83%, p-value
0.017).
Further, Michils and colleagues found that a decrease in FeNO of < 20% between two visits precluded asthma
control improvement (defined as a decrease ACQ < 0.5, NPV of 70%) and that an increase in FeNO < 30% was
unlikely to be associated with worsening in asthma control (ACQ improvement > 0.5, NPV of 86%). However,
when subjects were treated with moderate to high ICS doses, change in FeNO lost its ability to reflect an
improvement or worsening in asthma control. See Online Supplement 4 for details.
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3. Is FeNO lower in smoking than in non-smoking asthmatics?
Summary: Based on 15 studies FeNO levels are lower in smoking asthmatics than in non-smoking asthmatics
with the median of proportional difference being about 46 %.
In 15 out of the 16 studies providing data for this research question, FeNO levels were lower in smoking
asthmatics than in non-smoking asthmatics (18,32,35-48). However, the magnitude of difference between
smokers and non-smokers varied largely between studies (the proportional differences in FeNO values varied
from 28.4% (95% Cl 12.5% to 43.8%) to 71.8% (95% Cl 57.5% to 85%); median of the proportional differences
was 46.3  %;  medians  of  the lower  and upper  limits  of  95% CIs  were 36.9  % and 57.1  %,  respectively).  A
sensitivity analysis was undertaken to assess if inclusion of ex-smokers as non-smoking controls affected this
result. Eight of the 15 studies clearly reported only never-smokers having been used as controls. When the
analysis was restricted to these 8 studies only the results were similar (the proportional differences in FeNO
values  varied  from  28.7%  (95%  Cl  21.1%  to  36.1%)  to  71.8%  (95%  Cl  57.5%  to  85%);  median  of  the
proportional differences was 44.6 %; medians of the lower and upper limits of 95% CIs were 31.5 % and 57.7
%, respectively). There was incomplete information to deduce how known factors affecting FeNO value (such
as use of steroids, proportion of atopics and severity of asthma) influenced the marked differences between
studies (Online Supplement 6). In one study FeNO levels were similar among Japanese smokers and never-
smokers with asthma (41). In that particular study, sputum eosinophil count was high both in smokers and in
non-smokers  (mean  of  17.0  %  (SD  18.4)  and  of  11.5  %  (SD  20.0),  respectively),  and  thus  even  higher  in
smokers than in non-smokers. Detailed results and description of studies are presented in Online Supplement
5.
Although in majority of studies FeNO levels in smoking groups were significantly lower than in non-smoking
groups, it was not appropriate to synthetize quantitatively the average magnitude of the proportional
difference in FeNO levels between smoking asthmatics and non-smoking asthmatics because of clinical
diversity of participants e.g. regarding smoking habits and marked variation of differences in FeNO levels
between the studies.
4. Is FeNO among smoking asthmatics a) not on ICS-treatment or b) on ICS-treatment higher than among
healthy smoking individuals?
Summary: As compared to smoking healthy subjects, FeNO is increased in smoking asthmatics not on ICS-
treatment (six studies) but similar in ICS-treated smoking asthmatics (four studies).
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4a Smoking asthmatics not on ICS-treatment vs. smoking healthy subjects
In all six studies providing data for this comparison, FeNO levels were significantly higher in smokers with
asthma not on ICS-treatment than in healthy smokers (37,38,42,44,46,49). Detailed results and description
of studies are presented in Online Supplement 7. In five of these studies the proportional differences in FeNO
varied from 41.7% (95% Cl 24.1 to 58.6) to 81.8% (95% Cl 72.3 to 90.9) (Online Supplement 8). The largest
difference in FeNO values was in the Japanese study by Shimoda in 2016 (in smoking asthmatics not on ICS
mean FeNO was 77 ppb (SD 55 ppb) and in smoking healthy subjects mean FeNO was 14 ppb (SD 4 ppb), flow
rate of 50 mL/s) (44). In that study, sputum eosinophil count was high in smoking asthmatics (mean of 21%
(SD 18)). In one of the six studies 25 % of all asthmatics used ICS but there was no information how many
smoking asthmatics used ICS medication. In this study the proportional difference was lowest among all the
six studies (37.7% (95% Cl 28.1 to 46.9)).
4b Smoking asthmatics on ICS-treatment vs. smoking healthy subjects
Four studies (32,37,39,50) provided data for this comparison and they all concluded that FeNO levels in
smoking steroid-treated asthmatics did not differ from those in smoking healthy subjects (Online Supplement
7).
5. Can FeNO be used as aid in diagnosing asthma in smoking subjects?
Summary: There is incomplete information, but based on three studies with unclear risk of bias and different
setups and divergent results (two with positive and one with negative finding) there is some indication that
FeNO may be useful as aid in diagnosing asthma in smoking subjects.
The results of the three studies providing data for this research question were divergent. The study
populations in these studies were also different between each other. One study assessed the performance
of FeNO to differentiate asthmatics from non-asthmatics in a population sample of subjects with asthma-like
symptoms (38), while another study assessed the ability of FeNO to differentiate symptomatic asthmatics
from symptom free healthy subjects (49). The third study assessed the ability of FeNO to differentiate
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asthmatic subjects from a control group consisting of both symptomatic subjects without asthma and
symptom free healthy subjects (51).
Malinovschi and colleagues (38) concluded that FeNO could differentiate asthmatic subjects from non-
asthmatic subjects with asthma-like symptoms equally well in both never- and current smokers within a
random population sample (among smokers AUC = 0.70 (95% CI 0.59 to 0.82) for the optimum cut-point of
FeNO of 17 ppb, with sensitivity of 56.3%, specificity of 82.5%, PPV of 57% and NPV of 82%).
On the contrary, the study by Kostikas and colleagues (51) with heterogeneous sample of subjects concluded
that FeNO is not a good marker for the diagnosis of asthma in smokers (AUC = 0.648 (95% CI 0.53 to 0.76) for
the  optimum  cut-point  of  FeNO  of  19  ppb).  However,  FeNO  values  over  25  ppb  were  characterized  by
specificity over 90% also in smokers (specificity of 92.0% [95% CI 80.7 to 97.7] and sensitivity of 6.2% [95% CI
3.7 to 21.2]).
Matsunaga and colleagues (49) found that FeNO could differentiate symptomatic asthmatics from symptom
free healthy subjects, but the result was to some extent dependent on rhinitis status of subjects (among
smoking subjects without rhinitis: AUC = 0.935 for the optimum cut-point of FeNO of 18 ppb, with sensitivity
of 100% and specificity of 87%; among smoking subjects with rhinitis: AUC = 0.865 for the optimum cut-point
of FeNO of 22 ppb, with sensitivity of 80% and specificity of 86%).
We assessed all the three studies as having unclear risk of bias. In addition to some unclear information, all
the studies evaluated the diagnostic accuracy of FeNO against an optimal cut-off value derived from their
own data, but the study populations were rather small for adequate analyses. Description of the studies,
detailed results and risk of bias assessments are presented in Online Supplement 9.
Research questions 6-9
We found no studies providing data for these research questions.
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Discussion
To our knowledge this is the first systematic review to assess basic characteristics and clinical value of FeNO
in smokers with asthma. We found that there is some evidence on the basic relations between asthma and
FeNO in smoking subjects but lack of data to assess the clinical value of FeNO in diagnosis and treatment of
smoking subjects with asthma.
Basic characteristics of exhaled nitric oxide in smoking asthmatics
Although smoking decreases FeNO, we found that many of the basic relations of asthma and FeNO may hold
true also in active smokers. There is indication that FeNO may be associated with eosinophilic airway
inflammation also in smokers with asthma, FeNO is increased in untreated asthma but normal in ICS-treated
asthma as compared with healthy smokers. These are basically the same findings as in non-smokers but
absolute FeNO levels are lower.
The information on association of FeNO with eosinophilic airway inflammation in smoking asthmatics is
incomplete  as  there  were  only  three  studies  focusing  on  this  topic.  Based  on  two  studies  there  is  an
association between FeNO and eosinophilic airway inflammation, but one study did not support this. The
study by Hillas and colleagues (32) in smoking ICS-treated asthmatics found a clear association between FeNO
and induced sputum eosinophil count. Also the study by Schleich and colleagues (33) found a reasonable
accuracy for FeNO to identify airway eosinophilia. However, the study included steroid-naïve asthmatics and
those receiving ICS in low to high doses, but there was no detailed information on ICS use among smoking
asthmatics specifically. On the contrary, the study by Berry (31) with heterogeneous population of adult
asthmatics, did not find a correlation between FeNO and sputum eosinophils. In this study, it remained
unclear how many of the 113 smoking asthmatics used ICS treatment (56% of all study used inhaled steroids).
Thus, the conclusions in the two studies with heterogeneous populations were divergent. In the study by
Hillas 2011 with homogenous population, the number of smoking asthmatics (n= 40) was rather small for
adequate analysis (analyses were based on use of optimal cut-off values of FeNO derived from their own
data, in small sample size this may be a risk of bias (52)). The excluded study in this research question by
Nagasaki (41) considered the relationship between FeNO and eosinophilic inflammation in never- and ex-
smokers but not in current smokers.
Two cross-sectional studies evaluated whether single FeNO value is associated with asthma control and
concluded  that  FeNO  reflects  rather  poorly  asthma  control  in  smoking  asthmatics  (34,35).  This  is
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understandable as FeNO reflects activity of eosinophilic inflammation while symptom control is determined
also by lung function and possibly activity of non-eosinophilic inflammation. However, one of the two studies
found that changes in FeNO between control visits are related to simultaneous changes in asthma control in
smokers. However, they did not study whether changes in FeNO would predict future changes in asthma
control, which would be clinically more valuable.
Based on 15 cross-sectional studies FeNO levels in smoking asthmatics are lower than in non-smoking
asthmatics similarly as smoking decreases FeNO in healthy subjects. However, the magnitude of the
difference in FeNO values is unclear. There was marked variation between studies regarding inclusion criteria
of subjects, asthma severity and use of anti-inflammatory medication, proportion of atopics, and technical
details of FeNO measurement (e.g. exhalation flow rate). In many studies, there was incomplete or missing
information on these factors influencing FeNO. However, in most studies that reported these factors, they
were balanced between smoking and non-smoking groups. Important reasons for variation in the
proportional differences in FeNO values are probably differences in smoking habits of smokers. Our
sensitivity analysis showed that inclusions of ex-smokers (having quit at least 6 months earlier) did not affect
the results.
We found quite reliable data to show that FeNO is increased in smoking subjects with untreated asthma but
similar in smoking asthmatics on ICS-treatment, when compared to smoking healthy subjects. These findings
were both based on several studies (6 and 4, respectively) with similar results. This is an important finding
suggesting that FeNO might be useful in finding asthma also among symptomatic smokers similarly as FeNO
is recommended to be used in diagnostic workout of asthma in non-smokers (53).
Clinical value of FeNO in smoking asthmatics
This review found data for only one of the five research questions evaluating clinical value of FeNO in smokers
with asthma. Based on three studies with unclear risk of bias there is some indication that FeNO may be
useful as aid in diagnosing asthma in smoking subjects. However, the studies had different kinds of study
populations, different setups and somewhat divergent results.
The study by Malinovschi and colleagues had clinically most relevant setting of the three studies included, as
they evaluated the ability of FeNO to differentiate asthmatics from non-asthmatics among subjects with
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symptoms suggestive of asthma (38). The other two studies used either only asymptomatic healthy subjects
(49) or a combination of symptomatic non-asthmatics and healthy subjects (51) as the reference group.
We assessed all the three studies as having unclear risk of bias. In one study, it remained unclear whether
asthma diagnosis of all asthmatics fulfilled the criteria of this review (i.e. based on objective measures of lung
function) (38). In one study, it remained unclear how patients and controls were recruited (49). In addition,
all the three studies evaluated the diagnostic accuracy of FeNO against an optimal cut-off value derived from
data. It has, however, been stated that dichotomising continuous variables based on the data may lead to
overly optimistic measures of diagnostic accuracy (sensitivity and specificity) if the sample size is under 200
(52). Therefore, we decided to judge studies with under 200 participants (100 individuals without asthma
and 100 with asthma) as having unclear risk of bias. The sample sizes of the included studies varied from 49
to 112 subjects.
Clinical implications and guidance for future research
Although there is lack of studies on the role of FeNO in smokers with asthma, we found indication that FeNO
may be associated with eosinophilic airway inflammation also in smokers, FeNO is higher in asthmatic than
healthy smokers, and FeNO may be a useful aid in diagnosing asthma among smokers. However, cut-off
values of FeNO for possible clinical decision making probably need to be lower for smokers than for non-
smokers. In non-smoking adults, FeNO above 50 ppb suggests that eosinophilic inflammation and
responsiveness to corticosteroids are likely (54), while FeNO above 35 ppb is recommended to be considered
a positive test result in diagnostic workout of asthma (53). In the present review, the cut-off values of FeNO
in the included studies with smoking asthmatics were clearly lower than these presented for non-smoking
asthmatics: the suggested cut-off points in the two studies with positive results to detect airway eosinophilia
varied between 14 and 33 ppb (32,33) and the suggested cut-off points in two studies with positive results
in diagnosing asthma were 17 and 18 ppb (38,49). These cut-off values should, however be interpreted with
caution because the scarce and methodologically somewhat incomplete data does not allow making explicit
conclusions on cut-off values since most analyses were based on use of optimal cut-off values derived from
own data with relatively small sample size. Future analyses should be based on larger study populations (52).
Another important factor to bear in mind is different phenotypes of asthma and their relation to FeNO.
Asthma is a heterogeneous disease and eosinophilic airway inflammation is not present in all subjects with
asthma. As NO production and FeNO increase as a reaction to interleukin-13 (55), secreted in both allergic
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and non-allergic eosinophilic asthma, FeNO is more a marker of type 2 inflammation characterized by
mucosal eosinophilia than a marker of asthma or any other diagnostic label per se. However, most of the
research concerning FeNO in both smokers and non-smokers with asthma has been conducted in asthma in
general rather than specifically focusing on eosinophilic phenotypes of asthma. This causes variation and
inaccuracy and may cause false negative results on the ability of FeNO to provide clinically useful information.
Future research on FeNO in smokers should focus on the ability of FeNO to detect airway eosinophilia and to
predict ICS responsiveness in smokers with asthma. Clinical trials assessing the usability of FeNO in ICS dose
titration in individual subjects should optimally recruit only those smoking asthmatics who have eosinophilic
airway inflammation present in their asthma.
Potential sources of bias in the review process
We excluded studies reported only as abstracts and therefore some published data may have been left out
from the review. However, it has been shown that discrepancies occur between data reported as abstracts
or full reports and quality of data may not be sufficient if the results are reported as abstract only (26,27).
Further, although we had no restrictions on language or date of publication in literature search, we restricted
the selection of reports to studies published in English, German, Scandinavian languages or Hungarian.
Therefore, four potential reports (published in Polish, Japanese and Russian) were not evaluated for possible
inclusion in this review.
Conclusions
In conclusion, at the moment there is insufficient data to give specific guidelines on using FeNO in diagnosing
or guiding treatment of asthma in smoking subjects, but although smoking decreases FeNO it does not seem
to make FeNO redundant. According to current systematic review, there is some indication that FeNO may
be associated with eosinophilic inflammation also in smokers and FeNO may be useful in diagnosing asthma
among smoking subjects. As smoking is unfortunately common in subjects with asthma we encourage
researchers to conduct further trials on the clinical value of FeNO in this population.
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Criteria for anti-inflammatory medication
The criteria for anti-inflammatory medication depended on the study question as follows. In questions 1
and 2: no restrictions on ICS treatment. Question 3: both groups in a single study had to have similar status
regarding ICS treatment (i.e. both smoking and non-smoking asthmatics either on ICS or off ICSA). Question
4: no criteria for anti-inflammatory medication but we collected and reported the studies with ICS-treated
and non-treated subjects separately. Question 5: no restrictions on ICS treatment but use of medication
was taken into account in the assessment of risk of bias. Question 6: subjects had to be steroid-naïve;
question 7: subjects had to be on regular stable ICS and additional oral glucocorticoids were allowed; and
questions 8 and 9: subjects had to be on regular stable glucocorticoid treatment at baseline.
Comparisons
Requirements for comparisons in the included studies depended on the research questions as follows:
Question 1: comparison of FeNO against direct measures of eosinophilic airway inflammation (eosinophils
in sputum, bronchial biopsies or broncho-alveolar lavage) in smoking asthmatics.
Question 2: comparison of FeNO against conventional methods to assess asthma control or severity
(questionnaires, symptoms, lung function, exacerbations/hospitalisations, emergency visits, per oral
glucocorticoid use, need for add-on therapy) in smoking asthmatics.
Question 3: FeNO among smoking asthmatics compared to non-smoking asthmatics.
Question 4: FeNO among smoking asthmatics compared to healthy smoking individuals.
Question 5: diagnostic accuracy of FeNO measurement to identify asthma in comparison with lung function
measures.
Question 6 to 8: in smoking asthmatics, prognostic accuracy of: a) high FeNO value compared to low FeNO
value or, b) FeNO measurement compared to other clinical measurement (symptoms, lung function, blood
tests). Cut-off values for high and low FeNO taken from each original study instead of setting
predetermined values.
Question 9: tailoring of ICS treatment based on FeNO compared to usual treatment strategy.
Outcome measures and outcomes
Requirements for outcomes and outcome measures depended on the research questions as follows.
Questions 1 and 2: performance of FeNO described e.g. as sensitivity, specificity, positive predictive value
(PPV), negative predictive value (NPV), or area under receiver-operating characteristics (AUC of ROC) curve.
Questions 3 and 4: we accepted only studies in which FeNO was analysed as continuous variable (not
categorised or dichotomous variables).
Question 5: measures of diagnostic accuracy such as sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), the area under receiver-operating characteristics curve (AUC of ROC), or
likelihood ratios.
Questions 6 to 8:
· if  the  prognostic  accuracy  of  high  FeNO  value  was  compared  to  low  FeNO  value,  the  following
clinical outcomes had to be reported:
o asthma symptoms, lung function or exacerbations of asthma in questions 6 and 8
o exacerbations of asthma in question 7
· if the prognostic accuracy of FeNO measurement was compared to other clinical measurement
(symptoms, lung function, blood tests), accuracy of FeNO should be described e.g. as sensitivity,
specificity, positive predictive value (PPV), negative predictive value (NPV), or area under receiver-
operating characteristics curve (AUC of ROC).
Question 9: exacerbations of asthma, asthma symptoms, lung function, dose of inhaled steroids.
Quality assessment of the included studies
Assessment of risk of bias
In the research question 5, we assessed the risk of bias of included studies on FeNO’s diagnostic accuracy
by using the quality assessment tool of QUADAS-2 (1). It consists of four key domains covering patient
selection, index test, reference standard, and flow of patients through the study and timing of the index
test(s) and reference standard (“flow and timing”). The assessment tool was expanded by additional
signaling questions relevant to this review. To judge the study as having low risk of bias FeNO measurement
had to be performed before spirometry and the proportion of atopics had to be reported. In case FeNO
could not differentiate asthmatics from non-asthmatics, the proportion of subjects using ICS medication
had to be under 20 %. Further, FeNO should be analysed as a continuous variable or, when dichotomised,
this was based on reasonable cut-off values. If diagnostic accuracy of FeNO was evaluated e.g. against an
optimal cut-off value derived from data, we decided to judge the study having as unclear risk of bias if the
study population was under 200 (100 individuals without asthma and 100 with asthma).
To draw conclusions about the overall risk of bias within a study, we decided to classify the studies into
three categories: studies with low, unclear or high risk of bias. If all the domains within a study were graded
as  having  low  risk  of  bias,  the  overall  judgement  was  low  risk  of  bias.  If  even  one  of  the  domains  was
assessed as having high or unclear risk of bias, the overall risk of bias for a study was graded as high or
unclear, respectively.
Our intention was to assess risk of bias of included studies also in the other clinical research questions 6 to
9 with appropriate risk of bias assessment tool for each design (with the Quality In Prognosis Studies tool
QUIPS (2) in prognostic questions 6 to 8; and Cochrane risk of bias tool (3) in question 9, but there were no
included studies in these questions.
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3. Cochrane Database of Systematic Reviews (CDSR), Issue 5 of 12, May 2017
Service provider: Cochrane Library, Wiley
Date of search: 25 May 2017
Retrieved records: 1
#1 [mh ^"Nitric Oxide"] 1728
#2 [mh ^Exhalation] 174
#3 #1 and #2  61
#4 ((fraction* or exhal* or expir*) near/3 ("nitric oxide" or "nitrogen oxide" or "nitrogen
monoxide" or no)):ti,ab,kw 1148
#5 eno:ti,ab,kw  132
#6 feno:ti,ab,kw  289
#7 {or #3-#6}  1220
#8 [mh ^"Breath Tests"] 1470
#9 ((breath or breathing) near/3 test*):ti,ab,kw 2926
#10 {or #7-#9}  3934
#11 [mh ^Smoking] 6224
#12 (smoking or smoker* or tobacco or cigarette* or cigar? or pipe):ti,ab,kw
22348
#13 {or #11-#12}  22348
#14 [mh Asthma]  10008
#15 (asthma or asthmatic*):ti,ab,kw 26459
#16 [mh ^"Respiratory Hypersensitivity"]  217
#17 [mh ^"Bronchial Hyperreactivity"] 567
#18 ((airway? or bronchi or bronchial or respiratory) near/3 (hyperreact* or hyper-react* or
hypersensitiv* or hyperrespons*)):ti,ab,kw 1457
#19 (airway? near/3 inflammat*):ti,ab,kw  170
#20 {or #14-#19}  26803
#21 #10 and #13 and #20 in Cochrane Reviews (Reviews and Protocols)     1
3.1. Cochrane Database of Systematic Reviews (CDSR), Issue 9 of 12, September 2018
Service provider: Cochrane Library, Wiley
Date of search: 4 September 2018
Retrieved records: no records
Note: this is the strategy for the update search. New 2018 MeSH terms were added to line 11. The
Cochrane Library has gone through a revision during summer 2018 and DARE, NHS EED and
HTA databases are no longer included. Therefore, individual result numbers on lines 1-20 cannot
be compared against the result numbers in the original search.
1 [mh ^"Nitric Oxide"] 1923
#2 [mh ^Exhalation] 195
#3 #1 and #2  70
#4 ((fraction* or exhal* or expir*) near/3 ("nitric oxide" or "nitrogen oxide" or "nitrogen
monoxide" or no)):ti,ab,kw 624
#5 eno:ti,ab,kw 177
#6 feno:ti,ab,kw 484
#7 {or #3-#6} 1190
#8 [mh ^"Breath Tests"] 1476
#9 ((breath or breathing) near/3 test*):ti,ab,kw  3293
#10 {or #7-#9} 4297
#11 [mh ^Smoking] or [mh ”Tobacco Smoking”] or [mh ^”Pipe Smoking”] 133
#12 (smoking or smoker* or tobacco or cigarette* or cigar? or pipe):ti,ab,kw
27344
#13 {or #11-#12} 27380
#14 [mh Asthma] 10843
#15 (asthma or asthmatic*):ti,ab,kw 28951
#16 [mh ^"Respiratory Hypersensitivity"] 220
#17 [mh ^"Bronchial Hyperreactivity"] 578
#18 ((airway? or bronchi or bronchial or respiratory) near/3 (hyperreact* or hyper-react* or
hypersensitiv* or hyperrespons*)):ti,ab,kw 1562
#19 (airway? near/3 inflammat*):ti,ab,kw 219
#20 {or #14-#19} 29332
#21 #10 and #13 and #20 with Cochrane Library publication date between Jan 2017 and
Sep 2018, in Cochrane Reviews, Cochrane Protocols 0
4. Cochrane Central Register of Controlled Trials (CENTRAL), Issue 4 of 12, April 2017
Service provider: Cochrane Library, Wiley
Date of search: 25 May 2017
Retrieved records: 49
#1 [mh ^"Nitric Oxide"] 1728
#2 [mh ^Exhalation] 174
#3 #1 and #2  61
#4 ((fraction* or exhal* or expir*) near/3 ("nitric oxide" or "nitrogen oxide" or "nitrogen
monoxide" or no)) 1291
#5 eno 157
#6 feno 319
#7 {or #3-#6}  1378
#8 [mh ^"Breath Tests"] 1470
#9 ((breath or breathing) near/3 test*) 3094
#10 {or #7-#9}  4257
#11 [mh ^Smoking] 6224
#12 (smoking or smoker* or tobacco or cigarette* or cigar? or pipe)  25288
#13 {or #11-#12}  25288
#14 [mh Asthma]  10008
#15 (asthma or asthmatic*)  28917
#16 [mh ^"Respiratory Hypersensitivity"]  217
#17 [mh ^"Bronchial Hyperreactivity"] 567
#18 ((airway? or bronchi or bronchial or respiratory) near/3 (hyperreact* or hyper-react* or
hypersensitiv* or hyperrespons*)) 1640
#19 (airway? near/3 inflammat*) 219
#20 {or #14-#19}  29270
#21 #10 and #13 and #20 in Trials 49
4.1. Cochrane Central Register of Controlled Trials (CENTRAL), Issue 8 of 12, August 2018
Service provider: Cochrane Library, Wiley
Date of search: 4 September 2018
Retrieved records: 3
Note: this is the strategy for the update search. New 2018 MeSH terms were added to line 11. The
Cochrane Library has gone through a revision during summer 2018 and DARE, NHS EED and
HTA databases are no longer included. Therefore, individual result numbers on lines 1-20 cannot
be compared against the result numbers in the original search.
#1 [mh ^"Nitric Oxide"] 1923
#2 [mh ^Exhalation] 195
#3 #1 and #2 70
#4 ((fraction* or exhal* or expir*) near/3 ("nitric oxide" or "nitrogen oxide" or "nitrogen
monoxide" or no)) 682
#5 eno 207
#6 feno 501
#7 {or #3-#6} 1280
#8 [mh ^"Breath Tests"] 1476
#9 ((breath or breathing) near/3 test*) 3363
#10 {or #7-#9} 4456
#11 [mh ^Smoking] or [mh ”Tobacco Smoking”] or [mh ^”Pipe Smoking”] 133
#12 (smoking or smoker* or tobacco or cigarette* or cigar? or pipe) 29168
#13 {or #11-#12} 29204
#14 [mh Asthma] 10843
#15 (asthma or asthmatic*) 31012
#16 [mh ^"Respiratory Hypersensitivity"] 220
#17 [mh ^"Bronchial Hyperreactivity"] 578
#18 ((airway? or bronchi or bronchial or respiratory) near/3 (hyperreact* or hyper-react* or
hypersensitiv* or hyperrespons*)) 1752
#19 (airway? near/3 inflammat*) 262
#20 {or #14-#19} 31400
#21 #10 and #13 and #20 with Publication year from 2017 to 2018, in Trials 3
5. Database of Abstracts of Reviews of Effects (DARE)
Service provider: Centre for Reviews and Dissemination, https://www.crd.york.ac.uk/CRDWeb/
Date of search: 25 May 2017
Retrieved records: no records
1 MeSH DESCRIPTOR nitric oxide 58
2 MeSH DESCRIPTOR exhalation 12
3 #1 AND #2 5
4 ((fraction* or exhal* or expir*) NEAR3 (nitric oxide or nitrogen oxide or nitrogen
monoxide or no)) 41
5 (eno OR feno) 18
6 #3 OR #4 OR #5 45
7 MeSH DESCRIPTOR breath tests 68
8 ((breath or breathing) NEAR3 test*) 167
9 #6 OR #7 OR #8 202
10 MeSH DESCRIPTOR smoking 360
11 (smoking or smoker* or tobacco or cigarette* or cigar or cigars or pipe) 1602
12 #10 OR #11 1602
13 MeSH DESCRIPTOR asthma EXPLODE ALL TREES
14 (asthma or asthmatic*) 1232
15 MeSH DESCRIPTOR respiratory hypersensitivity 11
16 MeSH DESCRIPTOR bronchial hyperreactivity 10
17 ((airway* or bronchi or bronchial or respiratory) NEAR3 (hyperreact* or hyper-react*
or hypersensitiv* or hyperrespons*)) 33
18 (airway* NEAR3 inflammat*) 34
19 #13 OR #14 OR #15 OR #16 OR #17 OR #18 1245
20 #9 AND #12 AND #19 2
21 * IN DARE 45418
22 #20 AND #21 0
5.1. Database of Abstracts of Reviews of Effects (DARE)
Service provider: Centre for Reviews and Dissemination, https://www.crd.york.ac.uk/CRDWeb/
Date of search: 4 September 2018
Retrieved records: no records
Note: this is the strategy for the update search. New 2018 MeSH terms were included in lines 11-
12.
1 (MeSH DESCRIPTOR nitric oxide) 59
2 (MeSH DESCRIPTOR exhalation) 13
3 (#1 AND #2) 6
4 ((fraction* or exhal* or expir*) NEAR3 (nitric oxide or nitrogen oxide or nitrogen
monoxide or no)) 42
5 ((eno OR feno)) 19
6 (#3 OR #4 OR #5) 46
7 (MeSH DESCRIPTOR breath tests) 71
8 (((breath or breathing) NEAR3 test*)) 170
9 (#6 OR #7 OR #8) 205
10 (MeSH DESCRIPTOR smoking) 360
11 (MeSH DESCRIPTOR tobacco smoking EXPLODE ALL TREES) 0
Delete
12 (MeSH DESCRIPTOR pipe smoking ) 0
13 (smoking or smoker* or tobacco or cigarette* or cigar or cigars or pipe)
14 #10 OR #11 OR #12 OR #13 1603
15 (MeSH DESCRIPTOR asthma EXPLODE ALL TREES) 676
16 ((asthma or asthmatic*)) 1235
17 (MeSH DESCRIPTOR respiratory hypersensitivity) 11
18 (MeSH DESCRIPTOR bronchial hyperreactivity) 10
19 (((airway* or bronchi or bronchial or respiratory) NEAR3 (hyperreact* or hyper-react*
or hypersensitiv* or hyperrespons*))) 33
20 ((airway* NEAR3 inflammat*)) 34
21 #15 OR #16 OR #17 OR #18 OR #19 OR #20 1248
22 #9 AND #14 AND #21 2
23 * IN DARE 45418
24 #22 AND #23 0
6. Health Technology Assessment Database (HTA)
Service provider: Centre for Reviews and Dissemination, https://www.crd.york.ac.uk/CRDWeb/
Date of search: 25 May 2017
Retrieved records: no records
1 MeSH DESCRIPTOR nitric oxide 58
2 MeSH DESCRIPTOR exhalation 12
3 #1 AND #2 5
4 ((fraction* or exhal* or expir*) NEAR3 (nitric oxide or nitrogen oxide or nitrogen
monoxide or no)) 41
5 (eno OR feno) 18
6 #3 OR #4 OR #5 45
7 MeSH DESCRIPTOR breath tests 68
8 ((breath or breathing) NEAR3 test*) 167
9 #6 OR #7 OR #8 202
10 MeSH DESCRIPTOR smoking 360
11 (smoking or smoker* or tobacco or cigarette* or cigar or cigars or pipe) 1602
12 #10 OR #11 1602
13 MeSH DESCRIPTOR asthma EXPLODE ALL TREES
14 (asthma or asthmatic*) 1232
15 MeSH DESCRIPTOR respiratory hypersensitivity 11
16 MeSH DESCRIPTOR bronchial hyperreactivity 10
17 ((airway* or bronchi or bronchial or respiratory) NEAR3 (hyperreact* or hyper-react*
or hypersensitiv* or hyperrespons*)) 33
18 (airway* NEAR3 inflammat*) 34
19 #13 OR #14 OR #15 OR #16 OR #17 OR #18 1245
20 #9 AND #12 AND #19 2
21 * IN HTA 16941
22 #20 AND #21 0
6.1. Health Technology Assessment Database (HTA)
Service provider: Centre for Reviews and Dissemination, https://www.crd.york.ac.uk/CRDWeb/
Date of search: 4 September 2018
Retrieved records: no records
Note: this is the strategy for the update search. New 2018 MeSH terms were included in lines 11-
12. The database was closed for new records in 31 March 2018 and is no longer updated.
1 (MeSH DESCRIPTOR nitric oxide) 59
2 (MeSH DESCRIPTOR exhalation) 13
3 (#1 AND #2) 6
4 ((fraction* or exhal* or expir*) NEAR3 (nitric oxide or nitrogen oxide or nitrogen
monoxide or no)) 42
5 ((eno OR feno)) 19
6 (#3 OR #4 OR #5) 46
7 (MeSH DESCRIPTOR breath tests) 71
8 (((breath or breathing) NEAR3 test*)) 170
9 (#6 OR #7 OR #8) 205
10 (MeSH DESCRIPTOR smoking) 360
11 (MeSH DESCRIPTOR tobacco smoking EXPLODE ALL TREES) 0
Delete
12 (MeSH DESCRIPTOR pipe smoking ) 0
13 (smoking or smoker* or tobacco or cigarette* or cigar or cigars or pipe)
14 #10 OR #11 OR #12 OR #13 1603
15 (MeSH DESCRIPTOR asthma EXPLODE ALL TREES) 676
16 ((asthma or asthmatic*)) 1235
17 (MeSH DESCRIPTOR respiratory hypersensitivity) 11
18 (MeSH DESCRIPTOR bronchial hyperreactivity) 10
19 (((airway* or bronchi or bronchial or respiratory) NEAR3 (hyperreact* or hyper-react*
or hypersensitiv* or hyperrespons*))) 33
20 ((airway* NEAR3 inflammat*)) 34
21 #15 OR #16 OR #17 OR #18 OR #19 OR #20 1248
22 #9 AND #14 AND #21 2
23 * IN HTA FROM 2017 TO 2018 506
24 #22 AND #23 0
7. NHS Economic Evaluation Database (NHS EED)
Service provider: Centre for Reviews and Dissemination, https://www.crd.york.ac.uk/CRDWeb/
Date of search: 25 May 2017
Retrieved records: 2
1 MeSH DESCRIPTOR nitric oxide 58
2 MeSH DESCRIPTOR exhalation 12
3 #1 AND #2 5
4 ((fraction* or exhal* or expir*) NEAR3 (nitric oxide or nitrogen oxide or nitrogen
monoxide or no)) 41
5 (eno OR feno) 18
6 #3 OR #4 OR #5 45
7 MeSH DESCRIPTOR breath tests 68
8 ((breath or breathing) NEAR3 test*) 167
9 #6 OR #7 OR #8 202
10 MeSH DESCRIPTOR smoking 360
11 (smoking or smoker* or tobacco or cigarette* or cigar or cigars or pipe) 1602
12 #10 OR #11 1602
13 MeSH DESCRIPTOR asthma EXPLODE ALL TREES
14 (asthma or asthmatic*) 1232
15 MeSH DESCRIPTOR respiratory hypersensitivity 11
16 MeSH DESCRIPTOR bronchial hyperreactivity 10
17 ((airway* or bronchi or bronchial or respiratory) NEAR3 (hyperreact* or hyper-react*
or hypersensitiv* or hyperrespons*)) 33
18 (airway* NEAR3 inflammat*) 34
19 #13 OR #14 OR #15 OR #16 OR #17 OR #18 1245
20 #9 AND #12 AND #19 2
21 * IN NHSEED 17613
22 #20 AND #21 2
7.1. NHS Economic Evaluation Database (NHS EED)
Service provider: Centre for Reviews and Dissemination, https://www.crd.york.ac.uk/CRDWeb/
Date of search: 4 September 2018
Retrieved records: no records
Note: this is the strategy for the update search. New 2018 MeSH terms were included in lines 11-
12.
1 (MeSH DESCRIPTOR nitric oxide) 59
2 (MeSH DESCRIPTOR exhalation) 13
3 (#1 AND #2) 6
4 ((fraction* or exhal* or expir*) NEAR3 (nitric oxide or nitrogen oxide or nitrogen
monoxide or no)) 42
5 ((eno OR feno)) 19
6 (#3 OR #4 OR #5) 46
7 (MeSH DESCRIPTOR breath tests) 71
8 (((breath or breathing) NEAR3 test*)) 170
9 (#6 OR #7 OR #8) 205
10 (MeSH DESCRIPTOR smoking) 360
11 (MeSH DESCRIPTOR tobacco smoking EXPLODE ALL TREES) 0
Delete
12 (MeSH DESCRIPTOR pipe smoking ) 0
13 (smoking or smoker* or tobacco or cigarette* or cigar or cigars or pipe)
14 #10 OR #11 OR #12 OR #13 1603
15 (MeSH DESCRIPTOR asthma EXPLODE ALL TREES) 676
16 ((asthma or asthmatic*)) 1235
17 (MeSH DESCRIPTOR respiratory hypersensitivity) 11
18 (MeSH DESCRIPTOR bronchial hyperreactivity) 10
19 (((airway* or bronchi or bronchial or respiratory) NEAR3 (hyperreact* or hyper-react*
or hypersensitiv* or hyperrespons*))) 33
20 ((airway* NEAR3 inflammat*)) 34
21 #15 OR #16 OR #17 OR #18 OR #19 OR #20 1248
22 #9 AND #14 AND #21 2
23 * IN NHSEED FROM 2017 TO 2018 0
24 #22 AND #23 0
8. ClinicalTrials.gov
Service provider: https://www.clinicaltrials.gov
Date of search: 25 May 2017
Retrieved records: 24
Advanced search was used to run the search.
(exhaled nitric oxide OR feno OR eno) AND (asthma OR respiratory hypersensitivity OR broncial
hyperreactivity OR airway inflammation) AND smoking
8.1. ClinicalTrials.gov
Service provider: https://www.clinicaltrials.gov
Date of search: 4 September 2018
Retrieved records: 2
Note: this is the strategy for the update search.
Advanced search was used to run the search.
(exhaled nitric oxide OR feno OR eno) AND (asthma OR respiratory hypersensitivity OR broncial
hyperreactivity OR airway inflammation) AND smoking
First posted from 05/25/2017 to 09/04/2018
9. WHO International Clinical Trials Registry Platform (WHO ICTRP)
Service provider: http://apps.who.int/trialsearch/Default.aspx
Date of search: 25 May 2017
Retrieved records: 6
The search was run using the default search option.
exhaled nitric oxide AND asthma AND smok* OR feno AND asthma AND smok* OR eno AND
asthma AND smok* OR
exhaled nitric oxide AND respiratory hypersensitivity AND smoking OR feno AND respiratory
hypersensitivity AND smok* OR eno AND respiratory hypersensitivity AND smok* OR
exhaled nitric oxide AND bronchial hyperreactivity AND smoking OR feno AND bronchial
hyperreactivity AND smok* OR eno AND bronchial hyperreactivity AND smok* OR
exhaled nitric oxide AND airway inflammation AND smoking OR feno AND airway inflammation
AND smok* OR eno AND airway inflammation AND smok*
9.1. WHO International Clinical Trials Registry Platform (WHO ICTRP)
Service provider: http://apps.who.int/trialsearch/Default.aspx
Date of search: 4 September 2018
Retrieved records: 1
Note: this is the strategy for the update search.
The search was run using the default search option.
exhaled nitric oxide AND asthma AND smok* OR feno AND asthma AND smok* OR eno AND
asthma AND smok* OR
exhaled nitric oxide AND respiratory hypersensitivity AND smoking OR feno AND respiratory
hypersensitivity AND smok* OR eno AND respiratory hypersensitivity AND smok* OR
exhaled nitric oxide AND bronchial hyperreactivity AND smoking OR feno AND bronchial
hyperreactivity AND smok* OR eno AND bronchial hyperreactivity AND smok* OR
exhaled nitric oxide AND airway inflammation AND smoking OR feno AND airway inflammation
AND smok* OR eno AND airway inflammation AND smok*
The search retrieved seven records. The results were browsed for studies registered after the
original search in May 2017. One study was downloaded.
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Al-shamkhi 2016 Criteria of asthma diagnosis of subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but defined as self-reported
diagnosis of asthma and either asthma symptoms or asthma treatment).
Ewald-Kleimeier
2013
It remains unclear whether all subjects were asthmatics. Only eight smokers had
positive SIT (and were thus confirmed asthmatics).
Giovannelli 2016 Criteria of asthma diagnosis of the subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but defined as self-reported
diagnosis of asthma and either asthma symptoms or asthma treatment).
Grarup 2014 Criteria of smoking status of subjects included in the study did not fulfil the criteria
of smoking status assessed in this review. (The proportion of ex-smokers of all
subjects was 23% and thus exceeding the limit of 20% assessed in this review.
Subjects were defined as ex-smokers if they had stopped smoking before or when
the current pregnancy became known. Data of current smokers and ex-smokers
were combined in the analyses.)
Lappas 2016 Criteria of asthma diagnosis of the subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review; the report did not state
criteria of asthma diagnosis at all. (Subjects had sporadically symptoms and used
sporadically short-acting ß2-agonists).
Malinovschi 2009 Criteria of asthma diagnosis of subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but defined as self-reported
physician-diagnosis of asthma and at least one asthma symptom or one asthma
attack during the 12 months preceding the study).
Nadif 2010 Criteria of asthma diagnosis of subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but asthma diagnosis was based
on self-reported respiratory symptoms in the past 12 months or the use of inhaled
and/or oral medicines because of breathing problems).
Nguyen 2016 Criteria of asthma diagnosis of the subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but defined as self-reported
diagnosis of asthma).
FeNO value was not measured as continuous measure (but dichotomized).
Olin 2006 Criteria of asthma diagnosis of subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but defined as self-reported
diagnosis of asthma).
Rossios 2017 Criteria of smoking status of subjects included in the study did not fulfil the criteria
of smoking status of subjects assessed in this review (data of current smokers and
ex-smokers were combined in the analyses; there was no information on proportion
of ex-smokers. Data of 11 European countries were combined in the analyses).
Sastre 2013 Incomplete information on smoking asthmatic subjects. (The study was mainly
focused to investigate the usefulness of FeNO measurements for monitoring airway
response to SIC (specific inhalation challenge) with occupational agents.)
Taylor 2007 Criteria of asthma diagnosis of subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but defined as reported
diagnosed asthma with symptoms in the last 12 months).
Thorhallsdottir
2016
Criteria of asthma diagnosis of subjects included in the study did not fulfill the
criteria of the diagnosis asthma assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but defined as reported asthma
confirmed by a doctor and at least one respiratory symptom or at least one asthma
attack or use of medicines because of breathing problems in the 12 months at the
clinical interview).
Criteria of smoking status of subjects did not fulfil the criteria of smoking assessed in
this review (data of ex-smokers and never-smokers were combined in the analyses;
proportion of ex-smokers about 45% from all subjects).
Torre 2008 Criteria of smoking status of subjects included in the study did not fulfil the criteria
of smoking status of subjects assessed in this review (ex-smokers 34 % of subjects
but no detailed information when the subjects had quit smoking or criteria of ex-
smokers. In FeNO results, data of current smokers and ex-smokers were combined).
Additional information was inquired from the authors to assess the adequacy of the
study for this review (no response).
Yap 2013 Criteria of asthma diagnosis of subjects included in the study did not fulfill the
criteria of the asthma diagnosis assessed in this review (asthma was not diagnosed
based on reversible or variable airway obstruction but was frequently made by the
family physician).
Criteria of smoking status of subjects included in the study did not fulfil the criteria
of smoking status of subjects assessed in this review (data of current smokers and
ex-smokers were combined).
Westerhof 2015 Criteria of smoking status of subjects included in the study did not fulfil the criteria
of smoking status of subjects assessed in this review (data of current smokers and
ex-smokers were combined in the analyses. There was no information on the
proportion of ex-smokers, the total amount of current and ex-smokers was 54 % of
subjects).
Additional information was inquired from the authors to assess the adequacy of the
study for this review (no response).
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Characteristics of subjects FeNO measurement and










n = 566 asthmatics, of them current
smokers 113, males 44%
Demographics for all subjects (not
stated separately for the 113
smoking asthmatics):
Age (yr), mean (range): 49 (16-82)
Severity of asthma: no information
FEV1, % pred: no information
Steroid medication:
On ICS medication were 56% of
subjects, with average
beclomethasone equivalent dose
(µg) of ICS, median (range):
800 (200-4000).
On oral corticosteroid were 6%.
Atopy/allergy: atopics 51%




analyser (model LR2000, UK).





expressed as a percentage of
non-squamous cells based on
a count of 400 inflammory
cells.)
Percentage eosinophil count and FeNO
concentrations were log transformed for
analyses (to achieve normal distributions of
values).
Correlation coefficients were calculated using
Pearson's product-moment correlation co-
efficient.
Multiple independent regression was used to
examine the relationship between FeNO and
sputum eosinophil counts and the effect of
smoking, gender, ICS, age and FEV1 %
predicted on this relationship.
ROC (receiver operating characteristic) curves
were created to assess the performance of
FeNO to identify sputum eosinophil counts >
3% (separately for smokers and non-smokers).
AUCs (areas under the ROC curves) with 95%
confidence intervals and their differences from
0.5 were calculated.
FeNO values:
In smoking asthmatics: geometric mean of 2.8 ppb  (no information
on SD).
In the whole study group: geometric mean of 6.7 (0.65) ppb.
Sputum eosinophil count, % (for the whole study group): geometric
mean (log standard deviation): 2.3 (0.73).
Relationship of FeNO and eosinophil count:
In smoking asthmatics, significant positive correlation (R2 = 0.15, p
< 0.001).
AUC of ROC in smoking asthmatics:
The area under ROC (receiver operating characteristic) curve was
not significantly different from 0.5 for identifying a sputum eosinophil
count > 3%  (AUC = 0.63, 95% CI 0.48 to 0.78, p = 0.10)).
Reporting conclusion:
In smoking asthmatics, FeNO concentration did not relate closely to
sputum eosinophil count and did not predict the presence of a
sputum eosinophilia.
Online supplement 4
Research question 1     Descriptions and results of studies
Funding and Notes
Funging and conflict of interests:
Two authors were supported by research
grants from Asthma UK.
Notes:
No detailed information on confounding
factors of smoking asthmatics (e.g. on
asthma severity and use of steroids) and
on sputum eosinophil count of smokers.









n = 40 smoking asthmatics, males
45%
Age (yr), mean (± SD): 48.7 ± 11.2
Severity of asthma: mild to
moderate, well-controlled asthma
FEV1, % pred, mean (± SD):
87.8 ± 11.6
Steroid medication: all asthmatics
were receiving ICS.




Atopy/allergy: atopics 60% (based
on skin prick test)
Smoking habits, mean (± SD):




Flow rate: 50 ml/s
Reference standard:
Induced sputum eosinophil
count ≥ 3% (without sputum
neutrophilia)
Sputum induction was
performed according to the
European Respiratory society
guidelines.
A sample was considered
adequate when the patient
was able to expectorate at
least 2 ml of sputum.
Sputum cell counting was
performed by an observer who
was blind to the clinical
characteristics of the subjects.
ROC (receiver operating characteristic) curve
was created to assess the performance of
FeNO to identify purely eosinophilic phenotype
(sputum eosinophil counts  ≥ 3% and neutrophil
count <60 %).
AUCs (areas under the ROC curves) with 95%
confidence intervals and their differences from
0.5 were calculated.
Sensitivies, specificities, positive (PPV) and
negative (NPV) predictive values were
calculated for the optimal cut-points. The
optimal cut-off points were selected as those
points on the ROC curve that represented the
best combination of sensitivity and specifity.
FeNO values in smoking asthmatics:
median (interquartile range (IQR)): 12 (10-16).
Sputum eosinophil count, %: median (IQR): 2.0 (1.0-5.0).
Correlation of FeNO and eosinophil count:
Significant positive correlation (r = 0.71, p < 0.001).
Analysed by using Spearman's rank correlation coefficient.
Sputum phenotype was purely eosinophilic in 14/40 (35%) of
smoking asthmatics.
AUC of ROC:
The area under ROC (receiver operating characteristic) curve was
significantly different from 0.5 for identifying a sputum eosinophil
count ≥ 3% with a optimal FeNO cut-off value  > 14 ppb
(AUC = 0.880, 95% CI 0.74 to 0.96, p < 0.0001)).
Sensitivity, specificity, PPV, and NPV for the optimal FeNO cut-off





















n = 295, current smokers 58,
males of smoking asthmatics 53 %
Characteristics of smoking
asthmatics:
Age (yr), mean (range): 45.7 (23-81)
Severity of asthma: no information
FEV1, % pred, mean (± SD): 81 ± 19
Steroid medication: no information
Atopy/allergy: atopics 71%.









Logistic regression analysis was used to
assess the relationship between the binary
outcome (sputum eosinophil count ≥ 3%) and a
set of covariates, individually or in combination.
Covariates included FeNO (log-transformed),
age, gender, smokinfg, ICS and atopy.
Cut-off points on the FeNO scale were
determined in each case so that there was a
≥ 50% probability of a sputum eosinophil count
≥ 3%.
Sensitivity, specificity, positive predictive value
(PPV) and negative  predictive value (NPV)
were also calculated for each cut-off point from
the data.
FeNO values in smoking asthmatics:
median (IQR): 17 (12-37) ppb.
Sputum eosinophil count, %: median (IQR): 1.7 (0.2-8).
Simple logistic regression analysis assessing the effect of smoking
on the FeNO threshold for identifying sputum eosinophil count ≥ 3%:
sensitivity 76%, specificity 62%, PPV 59%, NPV 78%, for FeNO cut-
off value of 28 ppb, p-value 0.066 (information from online
supplement)
Multiple logistic regression analyses with covariates: smoking, atopy
and high dose of ICS:
PPVs ranging from 52% to 62% and NPVs ranging from 76% to
89%, depending on the covariates included in the analyses (the
FeNO thresholds ranged depending on the analysis).
Multiple logistic regression analysis including smoking and atopy
but no high dose of ICS in the analysis:
sensitivity 70%, specificity 68%, PPV 62%, NPV 76%, for FeNO cut-
off value of 33 ppb.
Reporting conclusion:
FeNO is able to identify the presence of sputum eosinophilia in
unselected patients with asthma with reasonable accuracy as long
as thresholds are adjusted for high doses of ICS, atopy and
Funging and conflict of interests:
No information provided.
Notes:
ROC curves were used to analyse the
ability of FeNO to detect purely
eosinophilic phenotype (sputum eos ≥ 3 %
and neutrophils < 60 %) instead of sputum
eos ≥ 3 %.
Analyses were based on use of optimal
cutoff values of FeNO derived from data.
The sample size (40) was rather small to
adequate analysis (Leeflang 2008).
Funging and conflict of interests:
Supported by Interuniversity Attraction
Poles (IAP) project P6/35 and by
unrestricted grants from GSK, Astra-
Zeneca and Novartis.
Notes:
No detailed information on confounding
factors of smoking asthmatics (e.g. on
asthma severity and use of steroids).
Analyses were based on retrospective
data.













that were evaluated in
the outpatient asthma
clinics of two tertiary
university hospitals
were included in the
study.
n = 274 asthmatics, of them current
smokers 82 (ICS-untreated smokers
32, ICS-treated smokers 50),
males 40%.
Demographics for all subjects (not
stated separately for the 83 smoking
asthmatics):
Age (yr), mean (± SD): 50 ± 17
FEV1, % pred, mean (± SD): 85 ± 19
Severity of asthma: no information
Steroid medication:
ICS-treated smokers 50 and ICS-
untreated smokers 32.
No information on dose.
Atopy/allergy: no information
provided





Flow rate: 50 mL/s
Reference standard:
Asthma control according to
Global Initiative for Asthma
(GINA) guidelines.
Classification was evaluated
by two asthma specialists
blinded to FeNO.
Comparison of FeNO measurement for the
identification of patients with not well-controlled
(i.e. partly controlled or uncontrolled) asthma
against asthma control status defined to GINA
guidelines.
ROC (receiver operating characteristic) curve
was created to assess the performance of
FeNO to identify of not well-controlled (i.e.partly
and uncontrolled) asthma.
AUCs (areas under the ROC curves) with 95%
confidence intervals and their differences from
0.5 were calculated.
Sensitivies, specificities, positive (PPV) and
negative (NPV) predictive values were
calculated for the optimal cut-points.
The diagnostic performance of FeNO for the
identification of not well-controlled asthma at
different cut-off points was also evaluated.
FeNO values:
Smoking ICS-untreated patients with uncontrolled and partly
controlled asthma had statistically significantly higher FeNO values
compared to those with well-controlled asthma (p < 0.05), median
(IQR):
uncontrolled 22 (21-108)
partly controlled  21(15-38)
well controlled 16 (12-19).
In ICS-treated smoking asthmatics the differences in FeNO values
between groups with different asthma control levels were not
statistically significantly different.
AUC of ROC:
In ICS-untreated smokers, AUC (95%) for the optimum cut-point of
FeNO > 19 ppb: 0.680 (0.492-0.833), p-value 0.059; indicating poor
diagnostic performance to identify not well-controlled asthma.
In ICS-treated smokers, AUC (95%) for the optimum cut-point of
FeNO > 23 ppb: 0.597 (0.449-0.733), p-value 0.256; indicating poor
diagnostic performance to identify not well-controlled asthma.
PPV: FeNO values > 30 ppb presented a PPV of 83% with ICS-
treated smokers, suggesting that high FeNO values are indicative of





design in this study
question.
Post hoc analysis of
database that was
continuously updated.
n = 59 smoking asthmatics , males
58%
Age (yr), mean (± SD): 38 ± 11
FEV1, % pred, mean (± SD):
86.2 ± 17.9
Asthma severity: no information
Steroid medication:
At baseline: ICS dose in μg
equivalents beclomethasone
diproprionate per day-1,
median (range): 500 (0-2000).
Asthma treatment was adjusted
according to the GINA guidelines,
regardless of FeNO value.
No information how many used ICS.
Atopy/allergy: atopics 92%
Smoking habit: no detailed
information reported.
Additional information obtained
from the authors: smoking at least
one cigarette per day for at least 1
FeNO measurement:
Device: Chemilumiscence
analyser (model LR2000, UK).





degree of impairment caused
by their asthma during the
preceding 7 days by
responding to six questions
using a seven-point scale
(Juniper).
Ability of FeNO measurement to identify
patients with controlled asthma defined as ACQ
scores < 1.5 was evaluated.
ROC (receiver operating characteristic) curve
was created and AUCs (areas under the ROC
curves) with 95% confidence intervals and their
differences from 0.5 were calculated.
Sensitivity, specificity, positive (PPV) and
negative (NPV) predictive values and accuracy
were stated for the optimal cut-off of FeNO
value
(value which best combined sensitivity and
specifity in the data).
In cross-sectional assessment, FeNO was unable to assess asthma
control in smoking asthma patients (cross-sectional part of the
study, one single FeNO measurement).
Sensitivity, specificity, PPV, NPV and accuracy for the optimal







At baseline: 25% (15/59) of the smoking subjects had controlled
asthma (ACQ score < 1.5).
Funging and conflict of interests:
AstraZeneca provided a grant for the
exhaled biomarker laboratory.
Notes:
No detailed information on asthma severity
of subjects and smoking habits.
No reporting whether the results differed
between subjects treated with low or high
ICS doses, although in methods section of
the report it is stated that patients treated
with low and high-to-moderate ICS doses
were considered separately.
Analyses were based on use of optimal
cutoff values of FeNO derived from data.
The sample size of smokers (59) was
perhaps too small  to adequate analysis
(Leeflang 2008).
Funding and conflicts of interests:
No information on funding provided.
One of the authors has received two
lecture fees and an unrestricted research
grant from Aerocrine.
Notes:
No information from smoking asthmatics
on asthma severity, dose of ICS in steroid-
treated subjects, proportion of atopics and
smoking habits. Only information that all
subjects had stable asthma.
Analyses were based on use of optimal
cutoff values of FeNO derived from
data.The sample sizes of smokers (32 and












n = 51 smoking asthmatics, males
51%
Age (yr), mean (± SD): 39 ± 11
FEV1, % pred, mean (± SD): 86.5 ±
18.0
Asthma severity: no information
Steroid medication:
Asthma treatment was adjusted
according to the GINA guidelines,
regardless of FeNO value.
At baseline: ICS dose in μg
equivalents beclomethasone
diproprionate per day-1,
median (range): 500 (0-2000).
No information how many used.
Atopy: atopics 92%
Smoking habit: no detailed
information reported.
Additional information obtained
from the authors: smoking at least




analyser (model LR2000, UK).





degree of impairment caused
by their asthma during the
preceding 7 days by
responding to six questions
using a seven-point scale
(Juniper).
ROC curves were used to analyse the ability of
change in FeNO between a pair of visits to
identify:
a) change from uncontrolled (ACQ score of ≥
1.5) to controlled (ACQ score of < 1.5) asthma
or vice versa.
b) significant improvement or worsening of
asthma control defined as a decrease or
increase in ACQ of ≥ 0.5.
Sensitivies, specificities, positive (PPV) and
negative (NPV) predictive values and accuracy
were stated for the optimal cut-off of FeNO
values.
Change from uncontrolled to controlled asthma between two
consecutive visits:
prevalence 33% (17/52), the highest NPV of 82% for cut-off value in
change of FeNO -20%, accuracy 67%, p-value 0.016.
Change from controlled to uncontrolled asthma between two
consecutive visits:
prevalence 25% (10/40), the highest NPV of 89% for cut-off value in
change of FeNO +50%, accuracy 83%, p-value 0.017.
Improvement of asthma control between two consecutive visits:
prevalence 43% (40/92), NPV of 70%, accuracy 66% and p-value <
0.001 for cut-off value in change of FeNO -20%.
When subjects were treated with a high ICS dose (>500 μg
equivalents of beclometasone diproprionate day-1, FeNO lost its
ability to assess a control improvement (p=0.07).
Worsening of asthma control between two consecutive visits,
assessed to FeNO cut-off value of +30%:
prevalence 28% (26/92), NPV of 86%, accuracy 74% and p-value <
0.001 for cut-off value in change of FeNO +30%.
When subjects were treated with a high ICS dose (>500 μg
equivalents of beclometasone diproprionate day-1, FeNO ability to
detect a worsening of control was somewhat reduced (p=0.037).
Reporting conclusion:
Sequential changes in FeNO are related to asthma control in
smokers.
An FeNO reduction of < 20% would indicate that asthma remains
uncontrolled in most smoking asthmatics. When asthma is
controlled, and FeNO increase of < 50% would indicate that asthma
Follow-up data
Funding and conflict of interests:
AstraZeneca provided a grant for the
exhaled biomarker laboratory.
Notes:
No detailed information on asthma severity
of subjects and smoking habits.
Analyses were based on use of optimal
cutoff values of FeNO derived from data.
The sample size of smokers (51) was
perhaps too small  to adequate analysis
(Leeflang 2008).
Study design FeNO measurement
Study reference, country,
study design Characteristics of smoking asthmatics FeNO measurement:flow rate, device











n = 17, males 29%
Age (yr), mean (range): 30 (19-48)
Severity of asthma: no information




Smoking habits, median (range):
8 (5-18) pack-years
Flow rate: 50 ml/s






No information how and
where the patients were
recruited.
n = 40, males 45%
Age (yr), mean (± SD): 48.7 ± 11.2
Severity of asthma: mild to moderate
FEV1, % pred, mean (± SD): 87.8 ± 11.6
Steroid medication:
all were receiving ICS.
ICS, n/mean budesonide equivalent dose: 10/400
ICS/LABA, n/mean budesonide equivalent dose:
30/640





Smoking habits, mean (± SD):
45.1 ± 20.2 pack-years
Flow rate: 50 ml/s
Device: NIOX MINO, Aerocrine,
Sweden
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n = 43,  males 40%
Age (yr), mean (± SD): 52.9 ± 15.2
Severity of asthma: mild to moderate
FEV1, % pred, mean (± SD): 88.3 ± 12.4
Steroid medication:
all were receiving ICS.
ICS, n/mean budesonide equivalent dose: 9/400
ICS/LABA, n/mean budesonide equivalent dose: 34/640





Non-smokers had never smoked.
Smoking steroid-treated asthmatic group had significantly lower
FeNO levels compared to non-smoking steroid-treated asthmatic
group (p < 0.001).
FeNO values:
In smoking asthmatics, median (interquartile range):
12 (10-16) ppb
In non-smoking asthmatics, median (interquartile range):
19 (14-25) ppb
Distributions of FeNO levels were skewed.
Statistical comparison of FeNO levels between smoking asthmatic
and non-smoking asthmatic groups was performed using Mann-
Whitney U-test.
Funging and conflict of interest:
No information provided
Characteristics of non-smoking asthmatics Results Funding and notes
Research question 3      Descriptions and results of studies
Characteristics of subjects NotesResults
n = 18, males 67%
Age (yr), mean (range): 30 (21-47)
Severity of asthma: no information
FEV1, % pred, mean (range):
95.2 (78.3 - 114.1)
Steroid medication: steroid-naive
Atopy/allergy: atopics 100%
Non-smokers included never smokers and ex-smokers
who had stopped smoking more than 6 months prior and
never exceeded 5 pack-years at any time
FeNO levels were significanty lower in smoking steroid-naive
asthmatics than in non-smoking steroid-naive asthmatics.
FeNO values:
In smoking  steroid-naive asthmatics, geometric mean (95% Cl):
16.72 (11.74, 23.82) ppb, measured pre-dose on Day 1 of placebo
treatment (summary of log-transformed data)
In non-smoking steroid-naive asthmatics, geometric mean (95% Cl):
53.40 (42.73, 66.75) ppb, measured pre-dose on Day 1 of placebo
treatment (summary of log-transformed data).
The FeNO levels were log-transformed before summarizing results.
Funging and conflict of interest:
Funding provided by GSK (GlaxoSmithKline)
Notes:
Gender imbalance in the smoking and non-smoking
groups, with a predominance of males in the non-
smoking group and females in the smoking group.
Sputum eosinophil counts were similar in both groups
measured pre-dose on Day 1 of placebo treatment






No information how and
where the patients were
recruited.
n = 22, males 55%
Age (yr), mean (± SEM): 30 ± 2
Severity of asthma: no information
FEV1, % pred, mean (± SEM): 94 ± 2
Steroid medication: steroid-naive
Sputum eosinophil count: no information
Atopy/allergy: no information
Smoking habits, mean (± SEM):
13 ± 2 pack-years









The aim of the study was





subjects was drawn from
the civil registration list.
Subjects were mailed




47% that responded, 686




Flow rate: 50 ml/s
Device: NIOX Mino, Aerocrine,
Sweden
Funging and conflict of interest:
Funded by an unrestricted grant from AstraZeneca. A.
Malinovschi was funded by Bror Hjerpsteds Stiftelse
and Uppsala University Hospital.
None of the authors have any conflcts of interest to
declare.
Notes:
Asthma diagnosis of all included asthmatics perhaps
do not fulfil the asthma diagnosis criteria of this review.
We, however, assumed that ≥ 80% of asthmatics
fulfilled the criteria.
FeNO values:
In smoking asthmatics, geometrical mean (95% CI):
16.7 (12.8, 21.7) ppb.
In non-smoking asthmatics, geometrical mean (95% CI):
24.4 (19.0, 31.3) ppb.
FeNO levels were not normally distributed and FeNO values were log-
transformed in the analyses. The comparison of smoking asthmatics
vs. non-smoking asthmatics was not tested.
n = in total 96 asthmatics: current smokers 32, never-smokers 45, ex-smokers 19, males 41%
Demographics for all asthmatic subjects (not stated separately for the 32 smoking or 45 never-smoking
asthmatics):
Age (yr), mean (SD):  32.7 (SD 8.7)
Severity of asthma: no information
FEV1, % pred, mean (SD): 94.4 (SD 15.2)
Steroid medication:
25% of asthmatics used ICS (no information on dose)
Sputum eosinophil count: no information
Atopy/allergy:
Rhinitis 65.6% in all asthmatics.
Atopics among all smokers 22% (not detailed for smoking asthmatics)
Smoking habits, median (range): 10 (0-30) pack-years.
This is information for all smoking subjects (n = 112)
Never-smoker group used as control group
n = 30, males 53%
Age (yr), mean (± SEM): 29 ± 1
Severity of asthma: no information
FEV1, % pred, mean (± SEM): 93 ± 1
Steroid medication: steroid-naive
Sputum eosinophil count: no information
Atopy/allergy: no information
No detailed information on non-smoking criteria but all
non-smokers were tested by NicCheck I which
determined the levels of nicotine and its metabolites, to
ensure non-smoking status.
FeNO levels were lower in smoking steroid-naive asthmatic subjects
than in non-smoking steroid-naive asthmatics.
FeNO values:
In smoking  steroid-naive asthmatics, median (range):
7.7 (3.4 - 32.5) ppb
In non-smoking steroid-naive asthmatics, median (range):
25.0 (9.7 - 92.8) ppb
Data were analysed non-parametrically. Comparisons between
groups were performed by Dunn's test.
Funging and conflict of interest:
Supported by a joint grant of the British Countil and and
Hungarian OMFB, a NATO Scientic Fellowship
Programme, the Hungarian National Scientific






The aim of the study was








n = 17, males 53%
Age (yr), mean (95% CI): 40.0 (35.5-52.0)
Severity of asthma: no information
FEV1, % pred, mean (95% CI):
75.4 (70.3-89.1)
Steroid medication: 81% of all asthmatics used
ICS (no information how many smoking
asthmatics used ICS).
Dose: ICS  (ug/d): 800 (100-900).
No oral steroids.
Sputum eosinophil count: no information
Atopy/allergy: 76% atopics
Smoking habits:
20.0 (17.5-27.5) cigarettes per day,
27.5 (16.0-35.7) pack-years
Flow rate: 250 mL/s
Device: chemilumiscence






The aim of study was to
investigate whether
changes in FeNO might
be related to changes in
asthma control in
smoking asthmatics.
Post hoc analysis of
database that was
continuously updated.
n = 59, males 58%
Age (yr), mean (± SD): 38 ± 11
Severity of asthma: no detailed information
FEV1, % pred, mean (± SD): 86.2 ± 17.9
At baseline: ICS dose in ug equivalents
beclomethasone diproprionate per day, median
(range): 500 (0-2000).
No information on how many used.
Sputum eosinophil count: no information
Atopy/allergy: atopics 92%
Smoking habit: no detailed information reported.
Additional information obtained  from the
authors: smoking at least one cigarette per day
for at least 1 year
Flow rate: 50 mL/s
Device: Chemilumiscence
analyser (model LR2000, UK),
n = 411, males 47%
Age (yr), mean (± SD): 41 ± 16
Severity of asthma: no detailed information
FEV1, % pred, mean (± SD): 85.6 ± 15.7
At baseline: ICS dose in ug equivalents beclomethasone
diproprionate per day,
median (range): 250 (0-2000).
No information on how many used.
Sputum eosinophil count: no information
Atopy/allergy: atopics 85%
Additional information obtained from the authors that the
criteria of non-smoking of this review are complied.
FeNO levels were significantly lower in smoking asthmatic subjects
than in non-smoking asthmatics (p < 0.001).
FeNO values:
In smoking asthmatics, geometric mean (geometrical interval): 18.1
(6.9-47.5).
In non-smoking asthmatics, geometric mean (geometrical interval):
33.7 (14.3-79.2).
Despite similar mean ACQ scores (1.5 in smoking asthmatics versus
1.7 in non-smoking asthmatics at baseline), FeNO was reduced in
smoking asthmatics.
Unpaired t-test were used when considering log-transformed FeNO
values.
Funging and conflict of interest:
AstraZeneca provided a grant for the exhaled
biomarker laboratory.
Notes:
No detailed information on asthma severity but it was
stated that:
25% (15/59) of the smoking subjects and 48%
(197/411) of the non-smoking subjects, at baseline,
were defined to have controlled asthma (classified
according to ACQ score < 1.5).
No detailed information on smoking habits.
n = 23, males 74%
Age (yr), mean (95% CI): 39.0 (33.0-52.0)
Severity of asthma: no information
FEV1, % pred, mean (95% CI):
81.4 (72.6-86.9)
Steroid medication: 81% of all asthmatics used ICS, (no
information how many non-smoking asthmatics used
ICS).
Dose: ICS  (ug/d): 400 (0-600).
No oral steroids.
Sputum eosinophil count: no information
Atopy/allergy: 96% atopics
Never-smoker group used as control group
Smoking asthmatic group had significantly lower FeNO levels
compared with non-smoking asthmatic group (p < 0.01).
FeNO values:
In smoking asthmatics, mean (95% CI):
4.03 (2.96-6.47) ppb
In non-smoking asthmatics, mean (95% CI):
14.30 (10.63-27.86) ppb
Difference between groups were tested by using the rank-sum test.
Funging and conflict of interest:
One of the authors was supported by a research grant
from the British National Flying Club.
Notes:
No detailed information how many smoking and non-
smoking asthmatics used ICS. Only information that 43















antenatal clinics and the
community.
n = 27, study with pregnant women
Age (yr), mean (± SD): 26.4 ± 5.9 (range 18-43)
Severity of asthma: severe asthma in 26%
FEV1, % pred, mean (± SD): 92.3 ± 15.1
Steroid medication, ICS (ug/day), median (IQR):
0 (0, 1000).
No information on how many used.
Sputum eosinophil count: no information
Atopy/allergy: no information
Pack-years, median (IQR):
4 (2.3-7.9) (8.5 years total smoking);
5-6 cigarettes per day





design related to FeNO
values.
The aim of the study was
to determine the effects
of smoking and age on
serum IgE levels and
eosinophilic inflammation
in patients with asthma.
Participants were
recruited at asthma clinic
of university hospital.
Asthma of patients were
newly diagnosed.
n = 46, males 63%
Age (yr), mean (± SD):
47 ± 13 (range 24-74)
Severity of asthma: no information
FEV1, % pred, mean (± SD): 91.3 ± 17.4
Steroid medication: steroid-naive
Sputum eosinophil count, %, mean (± SD): 17.0




Smoking habits, mean (± SD):
30 ± 19 pack-years,
Flow rate: 50 mL/s
Device: chemiluminescence
analyser, NOA 280, Sievers,
USA
n = 196, males 28%
Age (yr), mean (± SD):
49 ± 20 (range 16-95)
Severity of asthma: no information
FEV1, % pred, mean (± SD): 94.2 ± 22.1
Steroid medication: steroid-naive
Sputum eosinophil count,  %, mean (± SD):




Never-smoker group used as control group
FeNO levels in smoking asthmatic group did not differ from those in
non-smoking asthmatic subjects.
FeNO values:
In smoking asthmatics, mean (± SD): 55 ± 56
In non-smoking asthmatics, mean (± SD): 57 ± 60
FeNO levels were log-transformed to achieve normal distributions in
analyses.
Funging and conflict of interest:
No information provided but the authors declared that
they have no relevant conflicts of interest
n = 26, study with pregnant women
Age (yr), mean (± SD: 28.7 ± 4.2 (range 18-43)
Severity of asthma: severe asthma in 15.4%
FEV1, % pred, mean (± SD): 96.0 ± 14.0
Steroid medication: ICS (ug/day), median (IQR):
0 (0, 1000).
No information on how many used.
Sputum eosinophil count: no information
Atopy/allergy: no information
Never-smoker group used as control group
FeNO values:
In smoking asthmatics, median (IQR):
lowest FeNO: 8.3 (6.6.-16.9) ppb.
In non-smoking asthmatics, median (IQR):
lowest FeNO: 13 (10.1.-19.6) (in never-smokers group).
It remained unclear whether the FeNO levels were normally
distributed or not and which analysis method was used when
comparing the FeNO levels between the groups.
Funging and conflict of interest:
Financial support provided by the Asthma Foundation
of NSW, Hunter Medical Research Institute, Port











n = 46 (atopic 30), males 96%
Age (yr), mean (range): 19.5 (18-23)
Severity of asthma: symptomatic asthma, mild




Sputum eosinophil count: no information
Atopy/allergy:
atopics 65% (based on skin prick test)
Smoking habit, pack-years, mean (range):
atopics: 2.5 (0.2-9.0),
nonatopics: 4.2 (0.6-11)
Flow rate: 90-120 mL/s
Device: chemiluminescence






The aim of the study was
to investigate whether





No information how and
where the patients were
recruited.
n = 16, males 38%
Age (yr), mean (range): 30 (21-45)
Severity of asthma: no information
FEV1, % pred, mean (range): 81(41-107)
Steroid medication: steroid-naive
Sputum eosinophil count: no information
Atopy/allergy: atopics 100%
Smoking habits, mean (range):
9 (0-35) pack-years
Flow rate: 150 mL/s
Device: chemiluminescence
analyser CLD 700 AL, ECO
physics, Switzerland
n = 16, males 31%
Age (yr), mean (range): 28 (18-44)
Severity of asthma: no information
FEV1, % pred, mean (range): 77 (25-113)
Steroid medication: steroid-naive
Sputum eosinophil count: no information
Atopy/allergy: atopics 100%
No detailed information on non-smoking criteria but the
way of reporting gives an impression that non-smoking
group included never-smokers (the study had also an ex-
smoker group)
Smoking asthmatics tended to have lower FeNO consentrations than
non-smoking asthmatics, as measured with single-breath method
(p=0.08)
FeNO values based on single-breath method:
In smoking asthmatics, mean (± SD):
16.1 (10.1) ppb
In non-smoking asthmatic subjects, mean (± SD):
22.5 (14.5) ppb
Differences between groups in FeNO values with single-breath were
tested using analysis of variance (ANOVA).
Funging and conflict of interest:
No information provided
n =  70 (atopic 54),  males 86%
Age (yr), mean (range): 21 (18-30)
Severity of asthma: symptomatic asthma, mild




Sputum eosinophil count: no information
Atopy/allergy:
atopics 77% (based on skin prick test)
Additional information was obtained from the authors that
the non-smokers had not smoked for at least 6 months
previously and that they had smoked a maximum 99
cigarettes in their entire lives.
Median FeNO levels were significantly lower in steroid-naive
asthmatic smokers than in steroid-naive asthmatic non-smokers (p =
0.002).
FeNO values:
In smoking asthmatics, median (25-75% interquartile range) for
all smoking asthmatics:
13.5 (9.1 - 30.1) (not detailed for atopics/non-atopics). (Detailed result
obtained from author.)
In non-smoking asthmatics, median (25-75% interquartile range) for
all non-smoking asthmatics:
24.0 (14.9 - 40.1) (not detailed for atopics/non-atopics).
(Detailed result obtained from author.)
Because FeNO  was not normally distributed, log10-transformed
FeNO values were used in the analyses.
Comparison between groups were performed by one-way variance
analysis, and p-values were corrected for multiple comparisons by
the least significant difference method.
Funging and conflict of interest:







The aim of the study was










n = 52, males 63%
Age (yr), mean (± SD): 42 ± 13
Severity of asthma:
mild 73%; moderate 27%
FEV1, % pred, mean (± SD): 81 ± 20
Steroid medication: steroid-naive
Sputum eosinophil, %: 21 ± 18
Atopy/allergy: atopics 75%
Smoking habits, mean (± SD),
28 ± 14 pack-years
Flow rate: 50 mL/s
Device: chemiluminescence
analyser NOA 280, Sievers






The study aimed to test
the hypotheses that Calv is
raised and J'aw is
reduced in smokers with
asthma compared to non-
smoking asthmatics.
No information how and
where the patients were
recruited.
n = 22, males 45%
Age (yr), mean (SD): 46.6 (6.7)
Severity of asthma: mild to moderate
FEV1, % pred, mean (SD): 73.6 (18.5)
Steroid medication, ICS (mcg/day), mean (SD):
1046 (611)
Sputum eosinophil count, %: 0.4 (0.0, 1.0);
median (IQR) (104): 2.0 (0.0, 4.0)
Atopy/allergy: no information
Smoking habits, mean (SD):
27.6 (15.7) pack-years
Flow rate: 50 ml/s
Device: Niox-Flex, Aerocrine
Sweden
n = 21, males 48%
Age (yr), mean (SD): 42.5 (10.0)
Severity of asthma: mild to moderate
FEV1, % pred, mean (SD): 73.3 (15.3)
Steroid medication, ICS (mcg/day), mean (SD):
679 (419)
Sputum eosinophil count, %:  0.3 (0.0, 2.0);
median (IQR) (104): 1.0 (0.0, 7.0)
Atopy/allergy: no information
Non-smokers were never-smokers
FeNO values were significantly reduced in smoking asthmatics
compared to non-smoking asthmatics (p < 0.001).
FeNO values:
In smoking asthmatics, median (IQR): 11.1 (3.6, 13.5)
In non-smoking asthmatics, median (IQR): 32.8 (17.7, 73.2)
Comparison made using Mann-Whitney test.
Funging and conflict of interest:
Supported by the donation of a Niox-Flex machine and
educational grant from Aerocrine which covered
servicing and maintenance. Aerocrine had no
involvement in the study design, performance, analysis,
interpretation of data and manuscript preparation.
Notes:
In non-smoker group, daily ICS dose lower than in
smoker group (p < 0.05).
n = 81, males 25%
Age (yr), mean (± SD): 41 ± 12
Severity of asthma:
mild 86%;  moderate 14%
FEV1, % pred, mean (± SD): 84 ± 17
Steroid medication: steroid-naive
Sputum eosinophil, %: 32 ± 24
Atopy/allergy: atopics 62%
Non-smokers were never-smokers
FeNO levels were significantly lower in steroid-naive asthmatic
smokers than in non-smoking steroid-naive asthmatics (p < 0.01).
FeNO values:
In smoking asthmatics, mean (±SD):
77 ± 55
In non-smoking asthmatics, mean (±SD):
108 ± 88
t-test was used to compare baseline FeNO levels between groups.
Funding and conflicts of interest:
No external funding sources.

















70 asthmatics (11 current
smokers, 22 ex-smokers,





considered in this review.
n = 11, males 54.5%
Age (yr), mean (SD): 50.0 (10.6)
Severity of asthma: all subjects had severe
asthma
Post bronchodilator FEV1, % pred, mean (SD):
73.7 % (18.2)
Steroid medication:
Maintenance systematic steroids in 30%.
Oral steroid dose (mg/day), mean (SD):
 2.50 (4.71).
Maintenance ICS in 100%, no information on
dose.




Smoking history, mean (SD):
29.0 (18.2) pack-years
Flow rate: 50 ml/s
Device: no information on
device
n = 37, males 40.5%
Age (yr), mean (SD): 52.6 (13.3)
Severity of asthma: all subjects had severe asthma
Post bronchodilator FEV1, % pred, mean (SD): 68.6 %
(21.1)
Steroid medication:
Maintenance systematic steroids in 46%.
Oral steroid dose (mg/day), mean (SD):
4.18 (6.61).
Maintenance ICS in 100%, no information on dose.




No detailed information on non-smoking criteria but the
way of reporting gives an impression that non-smoking
group included only never-smokers (the study had also
an ex-smoker group)
FeNO values were significantly reduced in smoking asthmatics
compared to non-smoking asthmatics (p < 0.052).
FeNO values:
In smoking asthmatics, mean (± SD): 15.2 (16.6)
In non-smoking asthmatics, mean (± SD): 41.2 (36.3)
Comparison made using Kruskal-Wallis test.
Funding and conflict of interest:
Supported through an Innovative Medicines Initiative
joint undertaking under grant agreement 115010,
resources of which are composed of financial
contributions from the European Union's Seventh
Framework Programme (FP7/2007-2013) and
European Federation of Pharmaceutical Industries and







were patients with severe
refractory asthma
recruited to the British
Thoracic Society Severe
Asthma Registry.
n = 69, males 27%
Age (yr), mean (SD): 42 (10)
Severity of asthma: all subjects had severe
asthma
FEV1, % pred, mean (SD): 68 (19) (60 subjects,
number used to analyze incomplete data)
Steroid medication:
Maintenance oral steroids 32 %.
Oral steroid dose, median (IQR):
20 mg (11-30) (20 subjects, number used to
analyze incomplete data).
ICS: Beclomethasone dipropionate equivalent
dose (mg), median (IQR): 2 (1.6-2).
Sputum eosinophil count, %,  median (IQR):
1 (0-2) (14 subjects, number used to analyze
incomplete data)
Atopy/allergy:
At least 55 % of subjects reported some form of
allergic disease
Smoking habits, median (IQR):
19 (10-36) pack-years
(52 subjects, number used to analyze incomplete
data).
Flow rate: 50 ml/s









n = 13, males 62%
Age (yr), mean (SD):  33.9 (14.5)
Severity of asthma: mild
FEV1, % pred, mean (SD): 113.3 (17.2)
Steroid-medication: steroid-naive
Sputum eosinophil count: no information
Atopy/allergy: no information
Smoking habits, mean (SD), daily cigarette
consumption:
17 ± 6 during for 14 ± 6 years




n = 461, males 31%
Age (yr), mean (SD): 43 (14)
Severity of asthma: all subjects had severe asthma
FEV1, % pred, mean (SD): 70 (25) (406 subjects, number
used to analyze incomplete data)
Steroid medication:
Maintenance oral steroids 45%.
Oral steroid dose, median (IQR):
15 mg (10-20) (197 subjects, number used to analyze
incomplete data).
ICS: Beclomethasone dipropionate equivalent dose (mg),
median (IQR): 2 (1.6-2).
Sputum eosinophil count, %,  median (IQR):
4 (1-14) (106 subjects, number used to analyze
incomplete data)
Atopy/allergy:
At least 64 % of subjects reported some form of allergic
disease
Never-smoker group used as control group
FeNO values in smoking asthmatics were significantly reduced
compared to non-smoking asthmatics at baseline (p < 0.001).
FeNO values:
In smoking asthmatics, median (IQR): 14 (8-39)
(30 subjects, number used to analyze incomplete data)
In non-smoking asthmatics, median (IQR): 35 (20-65)
(184 subjects, number used to analyze incomplete data).
FeNO levels were not normally distributed and were logged for
analyses. Comparison made using Mann-Whitney U test.
Funging and conflict of interest:
no information provided.
Notes:
FeNO value available only from 30 out of 69 smoking
asthmatics and from 184 out of 461 non-asthmatics.
Demographics of subjects in this appendix are not
based on the 30 and 184 subjects from whom the
FeNO value was available.
n = 29, males 41 %
Age (yr), mean (SD): 36.1 (17.4)
Severity of asthma: mild
FEV1, % pred, mean (SD): 103.3 (10.6)
Steroid-medication: steroid-naive
Sputum eosinophil count: no information
Atopy/allergy: no information
Non-smokers were never-smokers
FeNO levels were significantly lower in steroid-naive asthmatic
smokers than in steroid-naive asthmatic non-smokers (p < 0.05).
FeNO values:
In smoking  steroid-naive asthmatics, mean (±SD):
12.7 ± 5.1
In non-smoking steroid-naive asthmatics, mean (±SD):
21.8 ± 12.7
The Kruskal-Wallis nonparametric analysis of variance test and
Dunn's multiple comparisons test were used to assess significant
differences in FeNO levels among the groups.
Log-aritmic transformation was done for FeNO values before
analysis.











Flow rate: 50 ml/s
Device: NIOX, Aerocrine
Sweden
Asthmatic smokers had 45.1% (95% CI 36.9 to 52.8) lower of FeNO
compared to non-smoking asthmatics.
FeNO levels were log-transformed to ensure normal distribution for
analyses.
Funding and conflicts of interest:
The authors report no conflicts of interest.
Notes:
No information on asthma severity but asthma attack in
the past year was reported in 49% of the asthmatics
and for 64% of subjects were prescribed asthma
medication.
Authors of the study commented:
Atopy was not considered as a potential confounding
factor in analyses.
Serum cotinine may introduce misclassifications of
exposure for smoking because the half-life of serum
cotinine averages about 17-20 h.
n = 1500, males 41%, no information on numbers of smokers and non-smokers.
Demographics for all asthmatic subjects (not stated separately for smoking and non-smoking asthmatics):
Age (yr), mean (SD): 36.7 (0.76). (FeNO was measured in 6-79 years olds.)
Severity of asthma: no information
FEV1, % pred: no information
Steroid medication: 33% of smokers and 28% of non-smokers reported use of oral/inhaled steroids in the
last two days, respectively (the number of non-smokers obtained from the authors).
Sputum eosinophil count: no information
Atopy/allergy: hay fever in the past year in 35%.
Cigarette smoking was assessed using both self-reported questionnaire and serum cotinine concentrations.
Participants with serum cotinine > 10ng/mL were categorized as current smoker, no matter how they
responded to the questionnaire.
Subjects whose serum cotinine was < 10ng/mL were categorized as current smokers, or former smokers or
non-smokers (based on the self-reporting for detailed questionnaire).















Proportion of asthmatics used ICS
medication Atopy Severity of asthma
Cahn 2015 16.72 17 53.4 18 35 68.7 54.3 to 82.9 steroid-naïve 100 % no information
Hillas 2011 12 40 19 43 83 36,8 26.5 to 47 100% used 60 % mild to moderate
Horvath 2004 7.7 22 25 30 52 69,2 55.8 to 80.8 steroid-naïve no information no information
Malinovschi 2012 12.8 32 24.4 45 77 47,5 36.4 to 58.4 25% used 22 % no information
McSharry 2005 4.03 17 14.3 23 40 71,8 57.5 to 85 81% used
76% of smokers;
96% of non-smokers. no information
Michils 2009 18.1 59 33.7 411 470 46,3 41.7 to 50.9
No information how many used.
ICS dose in ug equivalents
beclomethasone diproprionate per day,
median (range): 500 (0-2000)
90 % no information
Murphy 2010 8.3 27 13 26 53 36,2 22.6 to 49.1
No information how many used.






Nagasaki 2013 55 46 57 196 242 3,5 1.2 to 5.8 steroid-naïve
87% of smokers;
75% of non-smokers. no information
Rouhos 2010 13.5 46 24 70 116 43,8 34.5 to 53.4 steroid-naïve
65% of smokers;
77% of non-smokers. mild
Rutgers 1998 16.1 16 22.5 16 32 28,4 12.5 to 43.8 steroid-naïve 100 % no information




Spears 2011 11.1 22 32.8 21 43 66,2 51.2 to 79.1
No information how many used. In non-
smoker group, daily ICS dose lower
than in smoker group: (mcg/day),
mean (SD): 679 (419) vs.1046 (611)
(p < 0.05).
no information mild to moderate




Thomson 2013 14 69 35 461 530 60 55.8 to 64.2 100% used no information 100% had severe
Verleden 1999 12.7 13 21.8 29 42 41,7 26.2 to 57.1 steroid-naïve no information mild
Xu 2016 1500 45,1 36.9 to 52.8 30% used either oral or inhaledsteroids no information no information
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No information how and
where the patients were
recruited.
n = 22, males 55%
Age (yr), mean (± SEM): 30 ± 2
Severity of asthma: no information
FEV1, % pred, mean (± SEM): 94 ± 2
Steroid medication: steroid-naive
Sputum eosinophil count: no information
Atopy/allergy: no information
Smoking habits, mean (± SEM):
13 ± 2 pack-years
Malinovschi 2012, Denmark
Cross-sectional study desing
related to baseline FeNO
values.
The aim of the study was to
assess the value of FeNO to
diagnose asthma.
A random population sample
of 10,400 subjects was
drawn from the civil
registration list. Subjects
were mailed with a validated
self-administered asthma
and rhinitis screening
questionnaire. Of the 47%
that responded, 686 subjects
recorded two or more
respiratory symptoms and
were examined.
n = 96, current smokers 32, males 41%
Demographics for all asthmatic subjects (not
stated separately for the 32 smoking
asthmatics):
Age (yr), mean (SD):  32.7 (SD 8.7)
Severity of asthma: no information
FEV1, % pred, mean (SD): 94.4 (SD 15.2)
Steroid medication:
ICS use 25% (no information on dose)
Sputum eosinophil count: no information
Atopy/allergy:
rhinitis 65.6%.
Atopics among all smokers 22% (not detailed
for smoking asthmatics)
Smoking habits, median (range):
10 (0-30) pack-years.
This is information for all smoking subjects (n
= 112)
n = 186, current smokers 80, males 40%
Demographics for all subjects with non-specific
asthma symptoms (not stated separately for
the 80 smoking control subjects):
Age (yr), mean (SD): 32.7 (SD 8.9)
Control group in this study incorporated
subjects with non-specific asthma symptoms
but no objective signs of asthma in the
examination.
FEV1, % pred, mean (SD): 97.0 (SD 10.8)
Steroid medication:
ICS use 0.5% (no information on dose)
Atopy/allergy:
rhinitis 46.2%.
Atopics among all never-smokers 46% (not
detailed for control never-smokers)
Smoking habits, median (range):
10 (0-30) pack-years.
This is information for all smoking subjects (n =
112)
Flow rate: 50 ml/s
Device: NIOX Mino, Aerocrine,
Sweden
Smoking asthmatics had significantly higher FeNO levels than smoking
subjects with non-specific asthma symptoms (p < 0.001).
FeNO values:
In smoking asthmatics, geometrical mean (95% CI): 16.7 (12.8, 21.7) ppb.
In smoking non-asthmatics, geometrical mean (95% CI): 10.4 (9.1, 11.9) ppb.
In smoking asthmatics, the percentual increase of FeNO was 60% compared
to smoking non-asthmatics.
After adjusting, the corresponding figure was about 50% (figure taken from a
graph).
FeNO values were log-transformed for analyses (distribution of FeNO levels
was skewed to the right and normality assumption was used in analyses).
Percentual increase of FeNO in asthmatics vs. non-asthmatics was obtained
from linear regression models before and after adjusting for sex, height, age,
FeV1 (% pred), use of ICSs and pollen season (known determinants of
FeNO).
Funging and conflict of interest:
Funded by an unrestricted grant from
AstraZeneca. A. Malinovschi was funded by Bror
Hjerpsteds Stiftelse and Uppsala University
Hospital.
None of the authors have any conflcts of interest
to declare.
Notes:
We used never-smokers as control group
(including not ex-smokers) because there was no
information on e.g. when the ex-smokers had quit
smoking.
Asthma diagnosis of all included asthmatics
perhaps do not fulfil the asthma diagnosis criteria
of this review. We, however, assumed that ≥ 80%
of asthmatics fulfilled the criteria.
NotesCharacteristics of subjects FeNO measurement
n = 20, males 45%
Age (yr), mean (± SEM): 33 ± 2
FEV1, % pred mean (± SEM): 98 ± 1
Atopy/allergy: no information
Smoking habits, mean (± SEM):
12 ± 2 pack-year




Funging and conflict of interest:
Supported by a joint grant of the British Countil
and and Hungarian OMFB, a NATO Scientic
Fellowship Programme, the Hungarian National
Scientific Foundation and the Hungarian Ministry
of Health Care.
Characteristics of smoking healthy subjects FeNO measurement:flow rate, device Funding and notes
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Results
FeNO levels were significantly higher in steroid-naive asthmatic smokers than
in healthy smokers (p < 0.001).
FeNO values:
In smoking asthmatics, median (range):
7.7 (3.4 - 32.5)
In smoking healthy subjects, median (range):
3.2 (2.0 - 7.2)
Data were analysed non-parametrically. Comparisons between groups were
performed by Dunn's test.
Description and results of studies
Research question 4 A    Smoking asthmatics untreated with ICS vs. smoking healthy subjects
Matsunaga 2011, Japan
Cross-sectional study desing
related to baseline FeNO
values
This study evaluated FeNO
measurement as a
diagnostic test for asthma.
Subjects were recruited from
the outpatient clinic of
medical university.
n = 142, current smokers 52, non-smokers 90,
males 49%
Demographics for all asthmatic subjects (not
separately for smokers and non-smokers):
Age (yr), mean (±SE):  41.5 ± 1.4
Severity of asthma: no information
FEV1, % pred, mean (±SE): 89.1 ± 1.2
Steroid medication: steroid-naive
Sputum eosinophil count: no information
Atopy/allergy:
rhinitis 66%.
Smoking habits: no detailed information, only
mentioned that subjects were excluded from
the study if they had a smoking history with






conscripts referred to the




n = 46 (atopic 30), males 96%
Age (yr), mean (range): 19.5 (18-23)
Severity of asthma: symptomatic asthma, mild











related to baseline FeNO
values.
The aim of the study was to
evaluate influence of








n = 52, males 63%
Age (yr), mean (± SD): 42 ± 13
Severity of asthma: mild to moderate
FEV1, % pred, mean (± SD): 81 ± 20
Steroid medication: steroid-naive
Sputum eosinophil, %: 21 ± 18
Atopy/allergy: atopics 75%
Smoking habits, mean (± SD),
28 ± 14 pack-years
FeNO levels were significantly higher in steroid-naive asthmatic smokers than
in healthy smokers (p < 0.01).
The following FeNO value results are taken from a graph, from which the
standard deviations are  impossible to assess.
FeNO values:
In smoking asthmatics, mean: 36.3 ppb
In smoking healthy subjects, mean: 13.4. ppb
Normality assumptions were achieved by log-transformation of FeNO values,
back-transformed values were estimated.
Comparisons between groups were made by Mann-Whitney U test. Log-
transformed FeNO values were used in the analyses.
FeNO levels were significantly higher in steroid-naive asthmatic smokers than
in healthy smokers (p = 0.001).
FeNO values:
In smoking asthmatics, median (25-75% interquartile range):
all smoking asthmatics:
13.5 (9.1 - 30.1) (not detailed for atopics/non-atopics). (Detailed result
obtained from author.)
In smoking healthy subjects, median (25-75% interquartile range):
all smoking asthmatics:
7.3 (4.6 - 10.7) (not detailed for atopics/non-atopics). (Detailed result obtained
from author.)
Because FeNO  was not normally distributed, log10-transformed FeNO values
were used in the analyses.
Comparison between groups were performed by one-way variance analysis,
and p-values were corrected for multiple comparisons by the least significant
difference method.
FeNO levels were significantly higher in steroid-naive asthmatic smokers than
in healthy smokers (p < 0.001).
FeNO values:
In smoking asthmatics, mean (±SD):
77 ± 55
In smoking healthy subjects, mean (±SD):
14 ± 4
t-test was used to compare baseline FeNO levels between groups.
n = 224, current smokers 52, non-smokers
172, males 44%
Demographics for all healthy subjects (not
separately for smokers and non-smokers):
Age (yr), mean (±SE):  39.4 ± 0.9
FEV1, % pred, mean (±SE): 98.7± 0.6
Atopy/allergy:
rhinitis 45%.
Smoking habits: no detailed information, only
mentioned that subjects were excluded from
the study if they had a smoking history with
more than 20 pack-years.
Flow rate: 50 mL/s
Device: NIOX MINO (Aerocrine,
Sweden)
Funging and conflict of interest:
Supported by grant from the Ministry of Health,
Labour and Welfare, Japan.
Notes:
This study was only included in this comparison
smoking asthmatics vs. smoking healthy subjects
because there was no information available on
proportion of ex-smokers quitting smoking
between 3 to 6 months before the study started
(ex-smokers quitting smoking during 3 to 6
months before the study started were included in
the non-smoker group, issue which did not fulfil
the inclusion criteria of this review).
Flow rate: 50 mL/s
Device: chemiluminescence
analyser NOA 280, Sievers
Instruments Inc. Boulder, CO
Funding and conflicts of interest:
No external funding sources.
The authors have no conflicts of interest
n = 10, males 100%
Age (yr), mean (range): 19 (19-20)




3.7 (1.2 - 9.0)
Flow rate: 90-120 mL/s
Device: chemiluminescence
analyser, Sievers 270B, USA
Funging and conflict of interest:
Funded by non-profit foundations and supported
by Helsinki University Hospital
n = 14, males 50%
Age (yr), mean (± SD): 35 ± 6
FEV1, % pred, mean (± SD): 97 ± 17
Sputum eosinophil, %: 0.4 ± 0.5
Atopy/allergy: atopics 0%
Smoking habits, mean (± SD),





Subjects were recruited from
outpatients at university
outpatient asthma clinic.
n = 13, males 62%
Age (yr), mean (SD): 33.9 (14.5)
Severity of asthma: mild
FEV1, % pred, mean (SD): 113.3 (17.2)
Steroid medication: steroid-naive
Atopy/allergy: no information
Smoking habits, mean (SD), daily cigarette
consumption:
17 ± 6 during 14 ± 6 years
FeNO levels were significantly higher in steroid-naive asthmatic smokers than
in healthy smokers (p < 0.05).
FeNO values:
In smoking asthmatics, mean (±SD):
12.7 ± 5.1
In smoking healthy subjects, Mean (±SD):
7.4 ± 1.8
The Kruskal-Wallis nonparametric analysis of variance test and Dunn's
multiple comparisons test were used to assess significant differences in
FeNO levels among the groups. Log-aritmic transformation was done for
FeNO values before analysis.
n = 16, males 44%
Age (yr), mean (SD): 34.6 (9.1)
FEV1, % pred, mean (SD): 106.5 (SD 9.7)
Atopy/allergy: no information
Smoking habits, mean (SD), daily cigarette
consumption:
18 ± 7 during 16 ± 9 years















No information how and
where the patients were
recruited.
n = 40, males 45%
Age (yr), mean (± SD): 48.7 ± 11.2
Severity of asthma: mild to moderate, well-
controlled.
FEV1, % pred, mean (± SD): 87.8 ± 11.6
Steroid medication: all asthmatics were
receiving ICS.
ICS, n/mean budesonide equivalent dose:
10/400
ICS/LABA, n/mean budesonide equivalent
dose: 30/640
Sputum eosinophil count,
%,  median (IQR):
2.0 (1.0-5.0)
Atopy/allergy: atopy 60%






No information how and
where the patients were
recruited.
n = 10, males 50%
Age (yr), mean (± SEM): 31 ± 3
Severity of asthma: no information
FEV1, % pred, mean (± SEM): 89 ± 5
Steroid medication: all the asthmatics in this
comparison were receiving ICS.
BDP (beclomethasone diproprionate
equivalents per day, ug (range):
968 ± 99
Sputum eosinophil count: no information
Atopy/allergy: no information
Smoking habits, mean (± SEM):
11 ± 3 pack-years
Characteristics of smoking healthy subjects
n = 30, males 37%
Age (yr), mean (± SD): 47.2 ± 8.9
FEV1, % pred, mean (± SD): 99.4 ± 10.6
Atopy/allergy: no atopics
Smoking habits, mean (± SD:
39.8 ± 16.1 pack-years
Funging and conflict of interest:
Supported by a joint grant of the British Countil
and and Hungarian OMFB, a NATO Scientic
Fellowship Programme, the Hungarian National
Scientific Foundation and the Hungarian Ministry
of Health Care.
n = 20, males 45%
Age (yr), mean (± SEM): 33 ± 2
FEV1, % pred, mean (± SEM): 98 ± 1
Atopy/allergy: no information
Smoking habits, mean (± SEM):
12 ± 2 pack-years
Description and results of studies
Characteristics of subjects FeNO measurement
Study question 4 B   Smoking asthmatics treated with ICS vs. smoking healthy subjects
Results Notes
FeNO levels in smoking steroid-treated asthmatic group did not differ from
those in smoking healthy subjects (p > 0.05).
FeNO values:
In smoking asthmatics, median (interquartile range):
12 (10-16) ppb
In smoking healthy subjects, median (interquartile range):
12 (8-14) ppb
Distributions of FeNO levels were skewed and data are presented as medians
(interquartile range).
Statistical comparison of FeNO levels between smoking asthmatic and non-
smoking asthmatic groups was performed using Mann-Whitney U-test.
Funding and notes
Flow rate: 83-100 ml/s, Device:
chemiluminescence analyser,
R2000, Logan Research, UK
FeNO measurement:
flow rate, device
Flow rate: 50 ml/s
Device: NIOX MINO (Aerocrine,
Sweden)
Funging and conflict of interest:
No information provided
Results
There was no significant difference between steroid-treated asthmatic
smokers and healthy smokers (p > 0.05).
FeNO values:
In smoking asthmatics, median (range):
5.4 (1.7 - 12.0)
In smoking healthy subjects, median (range):
3.2 (2.0 - 7.2)
Data were analysed non-parametrically. Comparisons between groups were




related to baseline FeNO
values,
The aim of the study was to




Subjects were recruited from
respiratory outpatient clinics
and hospital staff.
n = 17, males 53%
Age (yr), mean (95% CI): 40.0 (35.5-52.0)
Severity of asthma: no information
FEV1, % pred, mean (95% CI):
75.4 (70.3-89.1)
Steroid medication: 81% of all asthmatics used
ICS, no detailed information for smoking
asthmatics.
ICS  (ug/d): 800 (100-900);
no oral steroids
Sputum eosinophil count: no information
Atopy/allergy: 76% atopics
Smoking habits:






No information how and
where the patients were
recruited.
n = 10, males 40%
Age (yr), mean (SD): 34.3 (10.2)
Severity of asthma: moderate
FEV1, % pred, mean (SD): 88.9 (12.4)
All asthmatics were treated with inhaled
corticosteroids but detailed information on the
medication not stated.
Sputum eosinophil count: no information
Atopy/allergy: no information
Smoking habits, mean (SD):
14.8 (8.2) pack-years
There was no significant difference between steroid-treated asthmatic
smokers and healthy smokers (p > 0.05).
FeNO values:
In smoking asthmatics, mean (SD):
6.10 (3.10)
In smoking healthy subjects, mean (SD):
9.40 (4.97)
Independent student t-test was used to compare baseline FeNO levels
between groups.
Funging and conflict of interest:
One of the authors was supported by a research
grant from the British National Flying Club.
n = 20, males 45%
Age (yr), mean (95% CI): 42.5 (36.7-46.0)




20.0 (20.0-25.0) cigarettes per day,
26.0 (14.5-32.6) pack-years
Flow rate: 250 mL/s
Device: chemilumiscence
analyser (model LR2000, UK)
n = 10, males 40%
Age (yr), mean (SD): 35.4 (14.0)
FEV1, % pred, mean (SD): 104.4 (9.4)
Smoking habits, mean (SD):
16.2 (21.9) pack-years
Flow rate: 50 ml/s
Device: NIOX MINO (Aerocrine,
Sweden)
Funging and conflict of interest:
No information on funding but no conflict of
interest
There was no difference between steroid-treated asthmatic smokers and
healthy smokers.
FeNO values:
In smoking asthmatics, mean (95% CI):
4.03 (2.96-6.47) ppb
In smoking healthy subjects, mean (95% CI):
4.71 (3.85-6.82) ppb
Difference between groups were tested by using the rank-sum test.










Horvath 2004 7,7 22 3,2 20 42 58.4 42.9 to 73.8
Malinovski 2012 16,7 32 10,4 80 96 37.7 28.1 to 46.9
Matsunaga 2011 36,3 52 13,4 52 104 63.1 53.8 to 72.1
Rouhos 2010 13,5 46 7,3 10 56 45.9 32.1 to 58.9
Shimoda 2016 77 52 14 14 66 81.8 72.3 to 90.9








subjects to the study
FeNO measurement and
reference standard Characteristics of study subjects Methods Results
Kostikas 2008,
Greece
Inclusion process of the
participants to the study:
Subjects giving at least one
positive answer to a
screening questionnaire of
respiratory symptoms
related to asthma were
considered eligible for the
study.
Subjects were excluded
if they had any of the
following: (1) previous
diagnosis of asthma or
rhinitis treated with
antiinflammatory medication,
(2) history of respiratory
tract infection within the past
6 weeks, and (3) recent
smoking cessation (< 2
months prior to the study).
Subjects (students) were





Device: NIOX MINO (Aerocrine, Sweden)
Flow rate: 50 mL/s
Reference standard:
Asthma was defined based on a history
of relevant lower respiratory tract
symptoms, along with one of the
following: significant bronchodilator
reversibility, positive methacholine
bronchial challenge test, or clinical and
spirometric response to a 4-week trial of
inhaled corticosteroids, prescribed after
FeNO measurements.
Diagnosis of asthma was established
after FeNO measurements, based on
evaluation by a resporatory physician
blinded to FeNO measurements under
prespecified criteria (GINA 2006).
In total 219 subjects (smokers 76), from whom diagnosed
asthmatics 63 (smokers 23), subjects with allergic rhinitis
57 (smokers 19), subjects with non-specific respiratory
symptoms 29 (smokers 11), and healthy controls 70
(smokers 23) (without no respiratory symptoms).
No demographics combined for the whole study group at
baseline.
Demographics for diagnosed asthmatics (n=63):
Males: 54%
Age (yr), mean (± SD): 21.6 ± 2.7
FEV1, % pred, mean (± SD): 84 ± 12
(differing from the corresponding figures among subjects
with allergic rhinitis (107 ± 11), subjects with nonspecific
symptoms (104 ± 12), and control subjects (109 ± 13) .




Smoking habits of smokers: no detailed information
ROC (receiver operating characteristic) curves
were created to assess the performance of
FeNO to identify asthmatic subjects, and AUCs
(areas under the ROC curves) with 95%
confidence intervals  were calculated.
Sensitivies and specifities with 95% confidence
intervals were stated for the optimal FeNO cut-
off point (point which provided the best
combination of sensitivity and specificity for the
diagnosis of asthma in the whole population).
Diagnostic performance was evaluated
separately taking into account factors like
allergic rhinitis and smoking.
Diagnostic performance of FeNO was evaluated
also using different cut-off points in the range of
10 to 30 ppb.
FeNO values per diagnosis, presented as median (interquartile
range):
In smoking asthmatics: 16.0 (9.0 - 20.5) ppb
In smoking subjects with allergic rhinitis: 16.0 (9.0 - 20.5) ppb
In smoking subjects with nonspecific symptoms: 9.0 (7.5 - 14.0)
ppb.
In smoking control subjects 9.0 (7.0 - 13.0) ppb.
AUC of ROC: smoking asthmatics vs. other smoking subjects):
AUC = 0.648 (95% CI 0.53 to 0.76) for the optimum cut-point of
FeNO of 19 ppb (which provided the best combination of
sensitivity and specificity for the diagnosis of asthma in the whole
population).
Sensitivity, and specificity for the FeNO cut-off value of 19 ppb:
Sensitivity: 29.2% (95% CI  12.7 to 51.1)
Specificity: 86.0% (95% CI  73.3 to 94.2)
Sensitivity, and specificity for the FeNO cut-off value of > 25 ppb
among smokers:
Sensitivity: 6.2% (95% CI 3.7 to 21.2)
Specificity: 92.0% (95% CI 80.7 to 97.7)
Reporting conclusion:
FeNO was not a good marker for the diagnosis of asthma in
smokers. However, FeNO values > 25 ppb were characterized by
specificity > 90% also in smokers.
Funging and conflict of interests:
No aknowledgements to business companies.
Notes: Subjects were recruited from
population by using symptom questionnaires
instead of recruiting subjects seeking medical
advice. Control group consisted partly of
symptom free healthy subjects, i.e. the focus
was not purely in ability of FeNO to
differentiate symptomatic asthmatics from
symptomatic non-asthmatics.
Assessment of risk of bias:
Unclear risk of bias.
1. Analyses were based on use of optimal cut-
off value of FeNO derived from the whole
data. When analysing performance of FeNO
at different cut-off points, the sample size of
smokers (76) was rather small to adequate
analysis.
2. No information on the proportion of atopics
among diagnosed asthmatics.
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Inclusion process of the
participants to the study:
A random population sample
of 10,400 subjects was
drawn from the civil
registration list. Subjects
were mailed with a validated
self-administered asthma
and rhinitis screening
questionnaire. Of the 47%
that responded, 686
subjects recorded two or
more respiratory symptoms
and were examined.
After examinations the final
number of the included
subjects was 282.
FeNO measurement:
Device: NIOX MINO (Aerocrine, Sweden)
Flow rate: 50 mL/s
Reference standard:
Asthma diagnosis was based on
presence of symptoms of asthma (i.e.
shortness of breath, chest tightness,
cough, exercise induced dyspnoea, night-
time awakenings, or respiratory
symptoms induced by allergen contact) in
combination with at least one of the
following:
1) Airway hyper-responsiveness (AHR) to
inhaled methacholine < 8.0 µmol.
2) At least 250 ml increase in FEV1 after
bronchodilator.
3) Daily use of systemic steroid, inhaled
steroid, or inhaled beta2-agonist.
4) Asthma symptoms during but not
outside the pollen season, eventually
supported by allergic rhinitis, although no
objective signs of asthma outside season
were found.
In total 282 subjects, from whom diagnosed asthmatics
96 (32 smokers), and subjects with non-specific asthma
symptoms 186 (80 smokers).
No demographics combined for the whole study group at
baseline.
Demographics for diagnosed asthmatics (n=96):
Males: 41%
Age (yr), mean (SD):  32.7 (8.7)
FEV1, % pred, mean (SD): 94.4 (SD 15.2)
Severity of asthma: no information
Steroid medication:
25% of asthmatics used ICS (no information on dose)
Atopy/allergy:
Rhinitis in 65.6% and IgE-sensitisation in 54.4 % of
asthmatics
(differing from the corresponding figures among subjects
with non-specific symptoms (46.2 % and 22.0 %).
Atopics among all smokers 22% (not detailed for
smoking asthmatics).
Smoking habits, median (range): 10 (0-30) pack-years.
This is information for all smoking subjects (n = 112)
The optimal cut-off for the ROC-curves was
defined as corresponding to the maximum value
of Youden's index (sensitivity + specificity-1). In
addition to optimal cut-off of FeNO, results are
presented to cut-offs for 90% sensitivity and
90% specificity.
Diagnostic performance of FeNO to identify
asthma was evaluated taking into account
smoking status.
FeNO values per diagnosis, presented as geometrical mean (95%
CI):
In smoking asthmatics: 16.7 (12.8, 21.7) ppb
In smoking subjects with non-specific symptoms: 10.4 (9.1, 11.9)
ppb
AUC of ROC in the population of smokers:
AUC = 0.70 (95% CI 0.59 to 0.82) for the optimum cut-point of
FeNO of 17 ppb.
Sensitivity: 56.3%; Specificity: 82.5%; PPV: 57%; NPV: 82%.
For 90% sensitivity, the cut-off point was 7 ppb:
At this cut-off point: Specificity: 15.1%; PPV: 32%; NPV: 89%.
For 90% specificity, the cut-off point was 22 ppb:
At this cut-off point: Sensitivity: 37.5%; PPV: 61%; NPV: 78%.
(Among never-smokers AUC = 0.72 (95% CI 0.62 to 0.82) for the
optimum cut-point of FeNO of 15 ppb, sensitivity of 77.8%,
specificity of  63.5%).
Reporting conclusion:
FeNO could differentiate asthmatic subjects from non-asthmatic
subjects with asthma-like symptoms equally well in both never- and
current smokers within a random population sample.
Funging and conflict of interests:
Funded by an unrestricted grant from
AstraZeneca. A. Malinovschi was funded by
Bror Hjerpsteds Stiftelse and Uppsala
University Hospital.
None of the authors have any conflcts of
interest to declare.
Notes:
Subjects were recruited from population by
using symptom questionnaires instead of
recruiting subjects seeking medical advice.
Assessment of risk of bias:
Unclear risk of bias.
1. Analyses were based on use of optimal
cutoff values of FeNO derived from data. The
sample size of smokers (112) was perhaps too
small to adequate analysis (Leeflang 2008).
2. Asthma diagnosis of all included subjects
perhaps do not fulfil the asthma diagnosis




Inclusion process of the
participants to the study:
Adult subjects with and
without respiratory
symptoms were recruited
from the outpatient clinic of
medical university.
Subjects were excluded
if they had a history of lung
diseases except for asthma,
had a smoking history with
more than 20 pack-years,
had had an airway infection




antagonists in the 4 weeks
preceding the study. Recent
quitters were also excluded
to stratify the study subjects
as either nonsmokers or
current smokers (within the
past 8 weeks).
FeNO measurement:
Device: NIOX MINO (Aerocrine, Sweden)
Flow rate: 50 mL/s
Reference standard:
Asthma was diagnosed on the basis of
the presence of significant airway
reversibility and/or airway
hyperresponsiveness during clinical
follow up period of 6 months after FeNO
measurements.
The diagnosis of asthma was established
after the FeNO measurements.
In total 366 subjects: from whom diagnosed asthmatics
142 (after the follow up period of 6 months) (52/142
smokers; 37%), and control subjects 224 (subjects
without respiratory symptoms, no history of asthma and
having normal spirometric parameters were included in
the control group) (52/224 smokers; 23%).
No demographics combined for the whole study group at
baseline.
Demographics for diagnosed asthmatics (n=142):
Males 49%.
Age (yr), mean (±SE):  41.5 ± 1.4
FEV1, % pred, mean (±SE): 89.1 ± 1.2
(differing from the corresponding figures among control
subjects (98.7 ± 0.6; p < 0.01).
Severity of asthma: no information
Steroid medication: steroid-naive
Atopy/allergy:
Allergic rhinitis in 66%.
Smoking habits: no detailed information, only mentioned
that subjects were excluded from the study if they had a
smoking history with more than 20 pack-years.
Receiver operating characteristic (ROC) curves
were plotted in order to estimate the cut-off
values for asthma diagnosis. An optimal cut-off
value was obtained from the highest sum
obtained from adding sensitivity and specificity.
Subjects were divided into four subgroups
according to allergic rhinitis and smoking status
and the cut-off values for each subgroup were
estimated.
Subgroups were: non-smoking subjects without
rhinitis, smoking subjects without rhinitis, non-
smoking subjects with rhinitis, smoking subjects
with rhinitis.
All these subgroups included subjects with
asthma and control subjects without respiratory
symptoms.
FeNO values:
In smoking asthmatics, mean: 36.3 ppb.
In smoking healthy subjects, mean: 13.4. ppb.
These FeNO values are taken from a graph, from which the
standard deviations are  impossible to assess.
AUC of ROC among smoking subjects without rhinitis:
(28 control subjects and 21 patients with asthma):
AUC = 0.935 for the optimum cut-point of FeNO of 18 ppb.
Sensitivity and specificity for the optimal FeNO cut-off value of 18
ppb:
Sensitivity: 100%; Specificity: 87%.
AUC of ROC among smoking subjects with rhinitis:
(24 control subjects and 31 patients with asthma):
AUC = 0.865 for the optimum cut-point of FeNO of 22 ppb.
Sensitivity and specificity for the optimal FeNO cut-off value of 22
ppb:
Sensitivity: 80%; Specificity: 86%.
Reporting conclusion:
The optimal cut-off values of FeNO to discriminate between the
subjects with asthma and those without asthma ranged from 18 to
28 ppb depending on rhinitis and smoking status.
Funging and conflict of interests:
Supported by grant from the Ministry of Health,
Labour and Welfare, Japan.
Notes: Control group consisted of symptom
free healthy subejcts, i.e. the focus was in
ability of FeNO to differentiate symptomatic
asthmatics from symptom free healthy
subjects.
Assessment of risk of bias:
Unclear risk of bias.
1.  Subgroup analyses were based on use of
optimal cutoff values of FeNO derived from
data. The sample sizes of smokers: 49
(smoking subjects without rhinitis) and 55
(smoking subjects with rhinitis) were rather
small to adequate analysis of estimating the
cut-off values for discrimation of asthmatics
and controls (Leeflang 2008).
2. It remains unclear how patients and controls
were recruited among hospital patients.
